[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 567
1. Shintaku I, Numahata K, Suzuki K, Ohyama C, Sato M, Saito S, Hoshi S, Orikasa S: [Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy]. Nihon Hinyokika Gakkai Zasshi; 2002 May;93(4):519-24
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of metastatic germ cell tumors with etoposide and cisplatin as first line chemotherapy].
  • PURPOSE: The efficacy and toxicity of two-drug therapy (etoposide and cisplatin, EP) in patients with metastatic germ cell tumors were investigated.
  • PATIENTS AND METHODS: Between December 1996 and November 1999, 18 patients with metastatic germ cell tumors (6 seminomas and 12 non-seminomas, Stage II 8, Stage IIIA 2, Stage IIIB 6, Stage IIIC 2) were treated by 3-5 cycles of induction chemotherapy regimen (EP).
  • RESULTS: At the end of EP therapy, 4 (22%) of the 18 patients achieved complete remission and 14 patients (78%) showed partial remission.
  • Seven patients of partial remission were treated by excision of residual abnormalities: 6 had pathologically necrotic debris in the resected specimen and 1 had teratoma, and these 7 patients all achieved complete remission.
  • Remaining three patients achieving partial remission received salvage chemotherapy with or without adjunctive surgery, resulted in complete remission in 2 patients and partial remission in 1 patient.
  • EP demonstrated to have less treatment-related toxicity compared with that of EBP.
  • Follow up studies ranging from 12 to 47 months (median, 29.6) showed that one patient experienced a relapse from complete remission at 13 months and was salvaged by chemotherapy and surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Male

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056035.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  •  go-up   go-down


2. Fernández AJ, Papí M, Espuch D, Chillón S, Talavera J: [Cervical metastasis from testicular teratoma]. Acta Otorrinolaringol Esp; 2002 Feb;53(2):141-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cervical metastasis from testicular teratoma].
  • [Transliterated title] Metástasis cervical de teratoma testicular.
  • The presence of neck metastasis in patients with testicular germ cell neoplasms in a rare but well known phenomenon.
  • The incidence of neck metastasis in testicular carcinoma has been reported to be present in a 5% of cases.
  • When cervical metastasis occurs, surgical resection of the residual disease following chemotherapy and using a specific technique of modified neck dissection results in a surprisingly improvement of the prognosis.
  • [MeSH-major] Bone Neoplasms / secondary. Clavicle / pathology. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11998529.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


3. Lee HM, Song SY, Park JO, Kim BH: Primary immature teratoma of the prostate with angiosarcoma component: its unusual response to chemotherapy. Int J Urol; 2006 Mar;13(3):305-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary immature teratoma of the prostate with angiosarcoma component: its unusual response to chemotherapy.
  • Here, we present a case of immature teratoma of prostatic origin, which included an angiosarcoma component.
  • This mass proved unresponsive against preoperative chemotherapy for immature teratoma.
  • Angiosarcoma, although quite rare, should be included in the differential diagnosis as a component of prostatic teratoma, especially in cases in which the tumor proves unresponsive to well-known chemotherapeutic protocols.
  • This is, to our knowledge, the first reported case of primary prostatic immature teratoma containing an angiosarcoma component.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hemangiosarcoma / drug therapy. Neoplasms, Multiple Primary. Prostatic Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Biopsy, Needle. Bleomycin / administration & dosage. Bleomycin / therapeutic use. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Diagnosis, Differential. Etoposide / administration & dosage. Etoposide / therapeutic use. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16643634.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


Advertisement
4. Kasai T, Moriyama K, Tsuji M, Uema K, Sakurai N, Fujii Y: Adenocarcinoma arising from a mature cystic teratoma of the testis. Int J Urol; 2003 Sep;10(9):505-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from a mature cystic teratoma of the testis.
  • Histopathological examination revealed a well-differentiated, mucinous adenocarcinoma originating from the gastrointestinal epithelium in a mature cystic teratoma (dermoid cyst) of the testis and metastatic mucinous adenocarcinoma of the skin.
  • We made a diagnosis of teratoma with malignant transformation (TMT) of the testis.
  • Combination chemotherapy with low-dose cisplatin/5'-deoxy-5-fluorouridine (CDDP/5'-DFUR) was initiated, but the patient died 8 months after orchiectomy.
  • At autopsy, similar mucinous adenocarcinoma of the testis and the skin were observed at the metastatic sites.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / secondary. Dermoid Cyst / diagnosis. Skin Neoplasms / secondary. Teratoma / diagnosis. Testicular Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12941133.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


5. Shoji H: [Clinical characteristics of non-herpetic limbic encephalitis]. Brain Nerve; 2010 Aug;62(8):853-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this review article,3 cases of NHALE patients with positive GluRepsilon2 antibody titers and ovarian-teratoma-related anti-N-methyl-D-aspartate receptor (NMDAR) antibody-positive encephalitis are briefly described.
  • Further, differential diagnosis for herpes simplex encephalitis is important in order to decide the initial treatment-antiviral drug therapy or immunological therapy.

  • Genetic Alliance. consumer health - Limbic encephalitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714033.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Interleukin-6; 0 / NR2B NMDA receptor; 0 / Receptors, N-Methyl-D-Aspartate
  •  go-up   go-down


6. Bilici A, Ustaalioglu BB, Seker M, Kayahan S: Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature. Clin Orthop Relat Res; 2010 Sep;468(9):2541-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: soft tissue metastasis from immature teratoma of the testis: second case report and review of the literature.
  • BACKGROUND: Testicular cancer, like other histopathologic types, commonly metastasizes to the lungs, liver, and brain.
  • Spread to soft tissue, however, is rare with only four cases with seminoma reported.
  • However, one case with metastasis of testicular immature teratoma to soft tissue was documented previously.
  • CASE DESCRIPTION: We report the case of a 38-year-old man with recurrent immature teratoma of the testis who presented with a painless soft tissue mass in the left thigh previously treated with standard chemotherapy.
  • After removal of the soft tissue mass, his serum alpha-fetoprotein level had returned to the normal range.
  • LITERATURE REVIEW: To our knowledge, this is the second case of immature teratoma of the testis metastasized to soft tissue.
  • PURPOSES AND CLINICAL RELEVANCE: We suggest that for a man with testicular cancer who has a soft tissue mass, metastasis of soft tissue from testicular cancer and other solid malignancies should be considered in the differential diagnosis of a soft tissue mass together with primary soft tissue sarcoma.
  • [MeSH-major] Soft Tissue Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Brain Neoplasms / therapy. Chorionic Gonadotropin, beta Subunit, Human / blood. Cranial Irradiation. Humans. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Magnetic Resonance Imaging. Male. Orchiectomy. Thigh. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Br J Radiol. 2008 Jul;81(967):e188-90 [18559897.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1644; author reply 1644 [12438072.001]
  • [Cites] Jpn J Clin Oncol. 2004 Apr;34(4):210-4 [15121758.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Urology. 1985 Apr;25(4):398-400 [2984822.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1165-71 [2998169.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):805-8 [2820673.001]
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1998 Oct;(355):272-81 [9917613.001]
  • [Cites] Acta Neurol Belg. 2005 Sep;105(3):178-9 [16255156.001]
  • [Cites] Eur Urol. 2005 Dec;48(6):885-94 [16126333.001]
  • [Cites] Singapore Med J. 2007 Mar;48(3):e77-80 [17342276.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] JAMA. 2008 Feb 13;299(6):672-84 [18270356.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • (PMID = 19937408.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  • [Other-IDs] NLM/ PMC2919860
  •  go-up   go-down


7. Chan KL, Tang MH, Tse HY, Tang RY, Lam HS, Lee CP, Tam PK: Factors affecting outcomes of prenatally-diagnosed tumours. Prenat Diagn; 2002 May;22(5):437-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of all fetuses referred to our institutions with antenatally-diagnosed tumours were reviewed for the type and location of the tumours, results of treatment and/or causes of death.
  • RESULTS: From January 1994 to May 2001, there were 15 fetuses with antenatally- diagnosed tumours: mesoblastic nephroma (MN) (n=2); neuroblastoma (NB) (n=2); cystic hygroma (CH) (n=3); intracranial germ cell tumour (IGCT) (n=2); sacrococcygeal teratoma (SCT) (n=3) and haemangioma (liver, n=2; limb, n=1).
  • One mother had termination of pregnancy for her fetal SCT.
  • One baby had cardiac failure resulting from a lower limb haemangioma and needed drug therapy.
  • All solid tumours (MN, NB, SCT) of the live births had no recurrence after surgery with or without adjuvant chemotherapy.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Pregnancy. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12001204.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Fujita K, Wada R, Sakurai T, Sashide K, Fujime M: Primary carcinoid tumor of the testis with teratoma metastatic to the para-aortic lymph node. Int J Urol; 2005 Mar;12(3):328-31
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the testis with teratoma metastatic to the para-aortic lymph node.
  • A primary testicular carcinoid tumor with teratoma metastasized to the para-aortic lymph node.
  • Chemotherapy consisting of cisplatin, etoposide and bleomycin was not effective on the metastatic lesions.
  • [MeSH-major] Carcinoid Tumor / surgery. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Abdominal. Humans. Lymph Node Excision. Lymphatic Diseases. Lymphatic Metastasis. Male. Middle Aged. Orchiectomy

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15828968.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


9. Serrano P, Fantova A, Pascual M, Allué M, Gil MJ, Rioja LA: [The treatment of metastasic testicular pure mature teratoma]. Arch Esp Urol; 2006 Jun;59(5):524-6
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The treatment of metastasic testicular pure mature teratoma].
  • [Transliterated title] Tratamiento del teratoma maduro puro de testiculo metastatizado. Qué hacer?
  • OBJECTIVE: Given the low frequency of testicular teratoma in relation to the rest of germ cell testicular tumors and the various treatment options for advanced stages, we report one case of advanced testicular mature teratoma with retroperitoneal adenopathy in which orchyectomy was performed after retroperitoneal lymphadenectomy, with the some pathology found in the primary tumor.
  • METHODS: We do an update on the treatment for these stages with the possibility of beginning with chemotherapy leaving lymphadenectomy for residual masses, or the contrary, being most cases treated in a mixed way.
  • CONCLUSIONS: Without clear evidence for guidelines in these tumors, it is recommended to individualize the treatment for each patient, accordingly to tumor characteristics, probability of relapse and follow-up.
  • [MeSH-major] Teratoma / secondary. Teratoma / surgery. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16903555.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Ponce de León Roca J, Villavicencio Mavrich H: [Growing teratoma syndrome]. Arch Esp Urol; 2000 Jul-Aug;53(6):547-52
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Growing teratoma syndrome].
  • [Transliterated title] Síndrome del "Growing teratoma".
  • OBJECTIVE: To review our series of patients with the growing teratoma syndrome (GTS) and to compare our results with those reported in the literature.
  • METHODS: We reviewed the clinical records of our series of patients with GTS for age, location of the tumor mass before and after chemotherapy, clinical stage according to the Royal Marsden Hospital Classification, histological pattern of the primary tumor, number and type of surgical procedures performed and clinical course.
  • RESULTS: There were 17 patients with GTS, accounting for 4.9% of the patients with nonseminomatous germ cell testicular tumors treated in our hospital.
  • The mean age at the time of diagnosis was 23 years.
  • Histological analysis of the primary tumor showed mature teratoma in 11, ectodermal sinus tumor in 8, and both histological types in 4.
  • The 25 retroperitoneal lymphadenectomy performed due to GTS account for 16.2% of the 154 retroperitoneal lymphadenectomies that were performed during the same time period.
  • Follow-up showed recurrence in 10 patients (58.8%); 7 had mature teratoma and 3 had malignant tumor.
  • CONCLUSIONS: Mature teratoma lesions can appear in different sites, the most frequent being the retroperitoneum and lung.
  • These lesions can appear before or during chemotherapy or after a disease-free interval.
  • The treatment of choice is resection of the mass, if possible in a single session to prevent malignant degeneration or compression of the adjacent structures.
  • We institute treatment early since an increase in size will make surgical treatment difficult, compromise organs and favor recurrence.
  • [MeSH-major] Teratoma. Testicular Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11002523.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] SPAIN
  • [Number-of-references] 25
  •  go-up   go-down


11. Sundström J, Pelliniemi LJ, Salminen E, Pöllänen P, Abdelwahid E, Veräjänkorva E, Söderström KO: Effect of etoposide on experimental testicular teratoma in 129/SvJ mice. Virchows Arch; 2000 Jun;436(6):608-16
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of etoposide on experimental testicular teratoma in 129/SvJ mice.
  • To study the effects of etoposide on experimental testicular teratoma in 129/SvJ mouse we analysed the tumour growth, differentiation, apoptosis and the localisation of mdr1 P-glycoprotein (mdr1-Pgp).
  • In this model the implanted gonadal ridges developed into testicular teratomas in 17 out of 56 implanted testes (30%) and in 14 out of 28 mice (50%).
  • The teratomas consisted mainly of neural tissue.
  • The etoposide-treated 4-week teratomas, but not the 6-week teratomas, were significantly smaller than those in the corresponding control groups.
  • The decreased proportion of immature neuroectodermal tissue components was observed in all treated teratomas, converting the histology towards that of a mature teratoma.
  • In addition, a low proportion of immature tissue components was frequently combined with a low density of apoptotic cells.
  • In conclusion, etoposide decreased the immature tissue components of teratomas, while mature tissues remained unaffected.
  • These results may have clinical relevance in man, since they confirm that postchemotherapy mature teratomas cannot be treated with chemotherapy.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Etoposide / therapeutic use. Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Animals. Apoptosis. DNA Fragmentation. Disease Models, Animal. Drug Resistance. Immunohistochemistry. Injections, Intraperitoneal. Male. Mice. Mice, Inbred Strains. P-Glycoprotein / analysis

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10917177.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / P-Glycoprotein; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


12. Carver BS, Al-Ahmadie H, Sheinfeld J: Adult and pediatric testicular teratoma. Urol Clin North Am; 2007 May;34(2):245-51; abstract x
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult and pediatric testicular teratoma.
  • Although pure testicular teratomas in prepubertal boys have not been reported to metastasize, testicular teratomas in adults are associated with clinical metastases in 60% of cases.
  • Teratoma has a diverse biological potential, with propensity for local growth, distant metastases, and transformation to somatic malignant cell types.
  • Teratoma is frequently found associated with other nonseminomatous histologies and is present in the retroperitoneum in 40% of postchemotherapy retroperitoneal lymph node dissections.
  • Because of the chemoresitant nature of teratomas, complete surgical resection is the treatment of choice.
  • Since the biology of teratoma is unpredictable and it is frequently found in the retroperitoneum following chemotherapy for nonseminomatous germ-cell tumors, complete control of the retroperitoneum is advocated for all patients regardless of residual mass size.
  • [MeSH-major] Teratoma. Testicular Neoplasms
  • [MeSH-minor] Adult. Clinical Trials as Topic. Humans. Male. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484929.001).
  • [ISSN] 0094-0143
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 36
  •  go-up   go-down


13. Donadio AC, Motzer RJ, Bajorin DF, Kantoff PW, Sheinfeld J, Houldsworth J, Chaganti RS, Bosl GJ: Chemotherapy for teratoma with malignant transformation. J Clin Oncol; 2003 Dec 1;21(23):4285-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for teratoma with malignant transformation.
  • PURPOSE: Teratoma with malignant transformation (MT) is a well-described entity that refers to the MT of a somatic teratomatous component in a germ cell tumor (GCT) to a histology that is identical to a somatic malignancy (eg, rhabdomyosarcoma [RMS]).
  • Surgical resection has been the mainstay of therapy for localized transformed disease because these tumors are thought to be resistant to standard treatment.
  • We report that chemotherapy has a role in selected patients with MT, determined by cell type.
  • PATIENTS AND METHODS: Chemotherapy was administered to 12 patients with MT of GCT limited to a single cell type (two patients with primitive neuroectodermal tumors, five with undifferentiated RMS, one with anaplastic small-cell tumor, two with adenocarcinoma, and two with leukemia); 10 patients had measurable disease.
  • Each patient received chemotherapy regimens based on the specific malignant cell observed in the transformed histology.
  • Three patients did not respond to treatment, and all of those patients died as a result of their disease.
  • CONCLUSION: Chemotherapy for MT limited to a single cell type may result in major responses and long-term survival in selected patients.
  • Local therapy after chemotherapy is an important component of treatment to achieve maximum response.
  • [MeSH-major] Cell Transformation, Neoplastic / drug effects. Mediastinal Neoplasms / drug therapy. Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Carcinoma / drug therapy. Carcinoma / pathology. Carcinoma, Small Cell / drug therapy. Carcinoma, Small Cell / pathology. Chemotherapy, Adjuvant. Cytogenetics. Humans. Leukemia, Mast-Cell / drug therapy. Leukemia, Mast-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Neuroectodermal Tumors, Primitive / drug therapy. Neuroectodermal Tumors, Primitive / pathology. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14645417.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Brames M, Ehrlich Y, Einhorn L: Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16121

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): Outcome analysis with PNET based chemotherapy.
  • : e16121 Background: Metastatic testis cancer is uniquely chemosensitive and highly curable.
  • Residual teratoma can be surgically resected.
  • However, testicular teratoma can differentiate along endodermal, ectodermal, or mesodermal elements (malignant transformation of teratoma), with capacity to metastasize and not be amenable to surgical resection.
  • We report results of malignant transformation of teratoma to metastatic PNET treated with PNET based chemotherapy.
  • METHODS: Retrospective review of 42 patients with PNET in testis or at metastatic sites seen at Indiana University from 1999-2007.
  • RESULTS: 9 of 10 patients had at least 1 prior platinum based combination chemotherapy regimen for their germ cell tumor.
  • Tumor markers (human chorionic gonadotropin and alphafetoprotein) were normal at start of chemotherapy for biopsy proven PNET.
  • Two of 10 are currently disease-free for 16 and 33 months from initiation of PNET specific chemotherapy and 3 other patients are alive with disease at 73, 34, and 30 months.
  • CONCLUSIONS: PNET specific chemotherapy has a high objective response rate for malignant transformation of teratoma to PNET, with some patients capable of long-term survival with chemotherapy followed by surgical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963389.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Wakhlu A, Misra S, Tandon RK, Wakhlu AK: Sacrococcygeal teratoma. Pediatr Surg Int; 2002 Sep;18(5-6):384-7
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacrococcygeal teratoma.
  • This retrospective study details our experience regarding 72 patients with sacrococcygeal teratoma treated over a period of 17 years.
  • The sex incidence was nearly equal, but there was a high proportion of Altmann type IV tumors.
  • A preliminary colostomy before combined abdominosacral excision of large type III and IV lesions reduced morbidity.
  • Imaging studies included radiography, abdominal ultrasound, computed tomography, and magnetic resonance imaging (after 1995).
  • Twenty-five patients had malignant teratomas.
  • Eight had a preliminary colostomy and chemotherapy followed by excision of the residual tumor and colostomy closure.
  • Of the latter 11 (who received cisplatinum-based chemotherapy), 10 were alive 1 year after surgery.
  • One patient is currently on preoperative chemotherapy and another developed recurrence of the tumor.
  • There should be no recurrence after excision of a benign teratoma.
  • Cisplatinum-based chemotherapy has improved the survival of patients with malignant tumors.
  • [MeSH-major] Teratoma / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Retrospective Studies. Sacrococcygeal Region

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12415361.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Zangana AM, Razak AB: A giant testicular teratoma. Saudi Med J; 2007 Mar;28(3):465-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A giant testicular teratoma.
  • We report a giant testicular in a 36-year-old farmer man, of 18-month duration admitted to the Surgical Department Erbil Teaching Hospital, Iraq.
  • Histological examination revealed mature and immature teratoma.
  • Six weeks later after a course of chemotherapy and radiotherapy, the patient underwent resection of metastatic lung lesion.
  • [MeSH-major] Lung Neoplasms / secondary. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology. Penile Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Follow-Up Studies. Humans. Immunohistochemistry. Iraq. Lymph Node Excision. Male. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334483.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


17. Chandrasekharam VV, Gupta AK, Bhatnagar V: Infantile gastric teratoma. Trop Gastroenterol; 2000 Oct-Dec;21(4):192-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile gastric teratoma.
  • Gastric teratoma is a rare tumour, comprising less than 1% of all teratomas in children.
  • A 5 month old male child, who presented with an abdominal mass, fever and vomiting was diagnosed to have a gastric teratoma on ultrasonography, CT scan and serum alpha-feto protein.
  • No chemotherapy was given.
  • The histological examination revealed immature teratoma.
  • [MeSH-major] Stomach Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11194585.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


18. Monzen Y, Okimoto T, Imafuku Y, Yamatogi S, Turudome T, Kimura S, Kiya K, Fukuhara T: [Chemoradiotherapy for neurohypophyseal immature teratoma]. Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr;65(2):127-30
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemoradiotherapy for neurohypophyseal immature teratoma].
  • We performed chemoradiotherapy for two patients (aged 6 and 33 years)with neurohypophyseal immature teratoma.
  • The patients received total doses of 40 to 50.6 Gy with concurrent carboplatin and etoposide.
  • Chemoradiotherapy is extremely effective in the treatment of neurohypophyseal immature teratoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / radiotherapy. Teratoma / drug therapy. Teratoma / radiotherapy
  • [MeSH-minor] Adult. Carboplatin / administration & dosage. Child. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920974.001).
  • [ISSN] 0048-0428
  • [Journal-full-title] Nihon Igaku Hōshasen Gakkai zasshi. Nippon acta radiologica
  • [ISO-abbreviation] Nihon Igaku Hoshasen Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


19. Iha T, Kano M, Nakayama M, Nagai Y, Moromizato H, Kanazawa K: Restoration of menstruation after chemotherapy-induced amenorrhoea in a patient with ovarian immature teratoma. Eur J Obstet Gynecol Reprod Biol; 2001 Oct;98(2):249-50
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Restoration of menstruation after chemotherapy-induced amenorrhoea in a patient with ovarian immature teratoma.
  • We described a rare case of a 20-year-old woman with an ovarian immature teratoma who resumed regular spontaneous menses after more than 5 years of chemotherapy-induced amenorrhoea.
  • Efforts to reverse chemotherapy-induced ovarian failure can be continued even after persistent menstrual dysfunction of 5 or more years.
  • [MeSH-major] Amenorrhea / chemically induced. Menstruation. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / adverse effects. Estrogens / therapeutic use. Female. Follicle Stimulating Hormone / blood. Humans. Luteinizing Hormone / blood. Medroxyprogesterone Acetate / therapeutic use. Ovary / drug effects. Ovary / physiology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Menstruation.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11574141.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Estrogens; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


20. El Mesbahi O, Terrier-Lacombe MJ, Rebischung C, Theodore C, Vanel D, Fizazi K: Chemotherapy in patients with teratoma with malignant transformation. Eur Urol; 2007 May;51(5):1306-11; discussion 1311-2
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in patients with teratoma with malignant transformation.
  • OBJECTIVE: Germ-cell tumours (GCTs) with a non-GCT malignant component are a unique and rare phenomenon called teratoma with malignant transformation (TMT).
  • The only published series of patients with TMT treated with chemotherapy comprised 10 patients.
  • Other histological types included adenocarcinoma (n=3) and bronchoalveolar carcinoma (n=1).
  • RESULTS: Primary treatment consisted of surgery alone in 4 patients.
  • The remaining 10 patients received first-line cisplatin-based chemotherapy with resection of residual masses (n=5): 4 patients had a complete response and 5 had a partial response.
  • Overall, 9 patients developed a relapse with a median time of 84 mo (range: 6-168).
  • At relapse, 8 patients received a chemotherapy regimen directed to the non-GCT component.
  • CONCLUSION: To our knowledge, this is by far the largest reported European series of chemotherapy in TMT.
  • Although TMT has a poor prognosis compared to GCT, its management may be improved by adapted chemotherapy associated with surgical resection of residual masses.
  • [MeSH-major] Neoplasms, Germ Cell and Embryonal / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Humans. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Middle Aged. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / pathology. Sarcoma / drug therapy. Sarcoma / pathology. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17081678.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


21. Nimkin K, Gupta P, McCauley R, Gilchrist BF, Lessin MS: The growing teratoma syndrome. Pediatr Radiol; 2004 Mar;34(3):259-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growing teratoma syndrome.
  • Growing teratoma syndrome is defined as enlarging masses of mature teratoma following chemotherapy for malignant nonseminomatous germ-cell tumors.
  • We describe clinical and imaging findings in a case of growing teratoma syndrome originating from immature teratoma of the ovary in a 12-year-old girl.
  • [MeSH-major] Neoplasm Recurrence, Local. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Female. Gynecologic Surgical Procedures / methods. Humans. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Int. 1995;55(4):226-8 [8588272.001]
  • [Cites] Clin Radiol. 1991 Jun;43(6):402-8 [2070582.001]
  • [Cites] Ann Med. 2002;34(5):316-23 [12452476.001]
  • [Cites] J Obstet Gynaecol Res. 2002 Jun;28(3):166-71 [12214834.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):942-7 [9307195.001]
  • [Cites] Gynecol Oncol. 1992 Dec;47(3):385-90 [1473754.001]
  • [Cites] Ann Thorac Surg. 1997 Aug;64(2):359-62 [9262575.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • (PMID = 14551755.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


22. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM: Malignant transformation of testicular teratoma: a chemoresistant phenotype. Urol Oncol; 2008 Nov-Dec;26(6):595-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of testicular teratoma: a chemoresistant phenotype.
  • PURPOSE: To review our experience in the management of malignant transformation of teratoma (MTT).
  • RESULTS: Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1).
  • Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND.
  • Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6.
  • CONCLUSIONS: In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment.
  • Alternative therapeutic strategies targeted to MTT are thus needed.
  • [MeSH-major] Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Drug Resistance, Neoplasm. Humans. Lymph Node Excision. Male. Neoplasm Staging. Retroperitoneal Space

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2781-8 [15837993.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1998 Jun;89(6):622-6 [9666691.001]
  • [Cites] Semin Urol Oncol. 1998 May;16(2):65-71 [9649229.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] Scand J Urol Nephrol. 2003;37(2):177-8 [12745729.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4285-91 [14645417.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [CommentIn] Urol Oncol. 2009 Mar-Apr;27(2):218; author reply 218-9 [19285238.001]
  • (PMID = 18367105.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS610854; NLM/ PMC4121060
  •  go-up   go-down


23. Porcaro AB, Antoniolli SZ, Martignoni G, Brunelli M, Curti P: Adult primary teratoma of the testis--report on 5 cases in clinical stage I disease. Int Urol Nephrol; 2001;33(4):657-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult primary teratoma of the testis--report on 5 cases in clinical stage I disease.
  • OBJECTIVES: Testis pure teratoma accounts for 2.7% to 3% of all germ cell tumors in adult where it behaves as a malignant neoplasm.
  • Pure teratoma of the testis presents in clinical stage I disease in 44% of the patients whose risk of having pathological stage II disease is 16.7% to 19.2%.
  • Herein we report on 5 cases of adult pure teratoma of the testis presenting itself in clinical stage I disease.
  • MATERIALS AND METHODS: From September 1976 to February 2000, 75 patients underwent orchidectomy for clinical stage I nonseminomatous germ cell cancer of the testis.
  • Testis pure teratoma was detected in 5 patients (7%).
  • Testis tumor markers were evaluated in all cases.
  • Treatment options after orchidectomy included retroperitoneal lymph node dissection (RPLND) in 4 patients and surveillance in 1.
  • Histopathology detected the following subtypes: mature teratoma in 3 cases (60%), immature teratoma in 1 (20%) and teratoma with malignant transformation in (20%).
  • Germ cell cancer microscopic metastatic disease including embryonal carcinoma was detected in I dissected lymph node of 1/4 patients (25%).
  • CONCLUSIONS: Primary pure teratoma of the testis does not respond to chemotherapy nor does it to radiation therapy.
  • The disease treatment options after orchidectomy for patients with clinical stage I disease include RPLND or surveillance with their relative risks and benefits.
  • RPLND is the chosen treatment because it is both staging and treating.
  • A close a long term follow up is required since pure teratoma metastatic disease may clinically develop after more than 10 years.
  • [MeSH-major] Orchiectomy. Teratoma / surgery. Testicular Neoplasms / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urol Clin North Am. 1999 Aug;26(3):595-609 [10494291.001]
  • [Cites] J Urol. 1975 Oct;114(4):636-9 [1235398.001]
  • [Cites] Prog Clin Biol Res. 1990;357:267-76 [2217471.001]
  • [Cites] J Urol. 1996 Mar;155(3):939-42 [8583612.001]
  • [Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]
  • [Cites] Lancet. 1987 Aug 8;2(8554):294-8 [2886764.001]
  • [Cites] J Urol. 1986 May;135(5):1020-2 [3959229.001]
  • [Cites] Virchows Arch. 2000 Jun;436(6):608-16 [10917177.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):564-8 [1312585.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):896-904 [9255252.001]
  • [Cites] Am J Surg Pathol. 1993 Nov;17(11):1075-91 [8214253.001]
  • [Cites] J Urol. 1997 Jan;157(1):160-3 [8976241.001]
  • [Cites] J Urol. 1998 Mar;159(3):859-63 [9474169.001]
  • [Cites] J Urol. 1998 Jan;159(1):133-8 [9400455.001]
  • [Cites] Cancer. 1995 May 1;75(9):2244-50 [7712432.001]
  • [Cites] Br J Urol. 1991 Feb;67(2):195-202 [2004236.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):860-3 [2990657.001]
  • [Cites] Urol Clin North Am. 1993 Feb;20(1):145-52 [8434433.001]
  • [Cites] Cancer. 1988 Sep 15;62(6):1202-6 [2842034.001]
  • [Cites] Br J Urol. 1994 Jun;73(6):701-6 [8032840.001]
  • (PMID = 12452623.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Mohanty SK, Balani JP, Parwani AV: Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature. Urology; 2007 Oct;70(4):812.e7-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor arising in a testicular teratoma with retroperitoneal metastasis: report of an interesting case with review of literature.
  • Teratomas with malignant transformation occur in approximately 3 to 6% of patients with metastatic germ cell tumors treated with platinum-based chemotherapy.
  • The histology of the nongerm cell (somatic) malignant elements most commonly includes carcinoma and various types of sarcomas; however, so far as the primitive neuroectodermal tumors (PNETs) are concerned the experience is quite limited.
  • There are only seven documented case reports and occasional series of PNET in association with testicular teratoma either in the primary site or in the metastatic location.
  • [MeSH-major] Neoplasms, Second Primary. Neuroectodermal Tumors, Primitive / pathology. Retroperitoneal Neoplasms / secondary. Teratoma / pathology. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17991577.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


25. Salunke P, Bhansali A, Dutta P, Bansal A, Gupta K, Vasishta RK, Singh P, Mukherjee KK: Congenital immature teratoma mimicking Cushing's disease. Pediatr Neurosurg; 2010;46(1):46-50
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital immature teratoma mimicking Cushing's disease.
  • A case of Cushing's syndrome due to congenital immature teratoma in the region of the pituitary has never been reported.
  • We discuss a case of a neonate who presented with Cushing's syndrome secondary to a congenital immature teratoma in sellar, suprasellar and parasellar regions with ectopic ACTH secretion, thereby mimicking Cushing's disease.
  • The management issues and prognosis of congenital teratomas and neonatal Cushing's syndrome have been discussed.
  • We describe the first case of intracranial ectopic ACTH secreting teratoma in a young infant.
  • In the preoperative period and in case of subtotal excision, chemotherapy to take care of hypercortisolemia may be given.
  • [MeSH-major] Brain Neoplasms / complications. Brain Neoplasms / pathology. Pituitary ACTH Hypersecretion / etiology. Pituitary ACTH Hypersecretion / pathology. Teratoma / complications. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516739.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


26. Noun M, Ennachit M, Boufettal H, Elmouatacim K, Samouh N: [The ovarian immature teratoma with gliomatosis peritonei]. J Gynecol Obstet Biol Reprod (Paris); 2007 Oct;36(6):595-601
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The ovarian immature teratoma with gliomatosis peritonei].
  • [Transliterated title] Tératome immature de l'ovaire avec gliomatose péritonéale. A propos d'un cas et revue de la littérature.
  • OBJECTIVE: We return a case of ovarian immature teratoma with peritoneal gliomatose at a woman aged of 20 years.
  • MATERIAL AND METHODS: The diagnosis discovered following pelvic mass increasing volume and treaty by a one-sided annexectomy, with chemotherapy.
  • CONCLUSION: Ovarian immature teratoma is a malignant germ cell tumor and represents less than 1% of ovarian malignant tumors.
  • Tissues are derived from the three germ layers (endo-, meso- and ectoderm).
  • Gliomatosis peritonei is a rare situation, characterized by the recurrence of peritoneal implants after the surgical treatment of ovarian teratoma.
  • This entity does not modify the good prognosis of mature teratomas, but we recommend regular follow-up.
  • [MeSH-major] Glioma / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537589.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Rana SS, Swami N, Mehta S, Singh J, Biswal S: Intrapulmonary teratoma: an exceptional disease. Ann Thorac Surg; 2007 Mar;83(3):1194-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapulmonary teratoma: an exceptional disease.
  • Intrathoracic teratomas almost always occur in the mediastinum, but occasionally, they may be found in the lung as intrapulmonary teratomas.
  • Intrapulmonary teratomas have histologic findings that are similar to those of teratoma from other sites.
  • Two successive patients with intrapulmonary teratomas presented to us in a variable manner.
  • [MeSH-major] Lung Neoplasms / pathology. Lung Neoplasms / surgery. Teratoma / pathology. Teratoma / surgery. Thoracic Surgical Procedures
  • [MeSH-minor] Abscess / etiology. Abscess / radiography. Abscess / surgery. Adult. Antitubercular Agents / therapeutic use. Drainage. Female. Humans. Lung Diseases / etiology. Lung Diseases / radiography. Lung Diseases / surgery. Recurrence. Thoracotomy. Tomography, X-Ray Computed. Tuberculosis, Pulmonary / complications. Tuberculosis, Pulmonary / drug therapy

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17307495.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antitubercular Agents
  • [Number-of-references] 7
  •  go-up   go-down


28. Iyoda A, Hiroshima K, Yusa T, Toyozaki T, Fujisawa T, Ohwada H: The primary mediastinal growing teratoma syndrome. Anticancer Res; 2000 Sep-Oct;20(5C):3723-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The primary mediastinal growing teratoma syndrome.
  • We encountered a case of mediastinal immature teratoma which revealed the feature of the so-called growing teratoma syndrome.
  • The specimen with percutaneous needle biopsy revealed mature teratoma.
  • The tumor was suspected to be mature teratoma with a malignant component because of the high level of serum AFP and he underwent chemotherapy.
  • The resected tumor was diagnosed as immature teratoma, although most of the tumor tissue was mature component.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cough. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Radiography, Thoracic. Syndrome. Treatment Outcome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268445.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 5
  •  go-up   go-down


29. Chang YL, Wu CT, Lee YC: Mediastinal and retroperitoneal teratoma with focal gastrointestinal adenocarcinoma. J Thorac Oncol; 2006 Sep;1(7):729-31
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal and retroperitoneal teratoma with focal gastrointestinal adenocarcinoma.
  • We report an unusual case of gastrointestinal adenocarcinoma arising in a giant posterior mediastinal mature cystic teratoma extending into the retroperitoneum, which was treated by complete excision with a good outcome for more than 2 years.
  • Teratomas with malignant transformation are rare non-germ cell malignant tumors arising from a preexisting mature teratoma.
  • In this report, we describe the potential aggressiveness of a giant mature cystic teratoma with adenocarcinoma and suggest that complete surgical resection without adjuvant chemotherapy be considered as a therapy in the treatment of teratoma with focal malignant transformation.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrointestinal Neoplasms / pathology. Mediastinal Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409945.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Goswami D, Sharma K, Zutshi V, Tempe A, Nigam S: Nongestational pure ovarian choriocarcinoma with contralateral teratoma. Gynecol Oncol; 2001 Feb;80(2):262-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nongestational pure ovarian choriocarcinoma with contralateral teratoma.
  • CASE: We describe a case associated with mature cystic teratoma of the contralateral ovary.
  • Details of all 30 cases including clinical features, associations, surgicopathological findings, operative procedures, postoperative chemotherapy, and outcome are summarized.
  • CONCLUSION: This rare malignancy responds well to surgery and postoperative chemotherapy including the methotrexate-based regimes.
  • [MeSH-major] Choriocarcinoma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11161870.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  •  go-up   go-down


31. Sarkar A, Roy PP, Dey SK, Dwari AK, Bandyopadhyay R, Chakraborty K, Das A: Mediastinal teratoma mimicking massive pleural effusion. J Assoc Physicians India; 2010 Jul;58:453-5
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal teratoma mimicking massive pleural effusion.
  • Immature mediastinal teratoma is very rare, found in only 1% of all mediastinal teratomas.
  • Surgery and adjuvant chemotherapy are keys in the management, especially in patients older than 15 years of age.
  • Raised serum marker as well as excision biopsy of the mediastinal mass following thoracotomy were indicative of a diagnosis of immature teratoma.
  • [MeSH-major] Mediastinal Neoplasms / diagnosis. Pleural Effusion / radiography. Teratoma / diagnosis
  • [MeSH-minor] Adolescent. Biopsy, Fine-Needle. Chorionic Gonadotropin, beta Subunit, Human / blood. Diagnosis, Differential. Humans. Lost to Follow-Up. Male. Radiography, Thoracic. Thoracotomy. Tomography, X-Ray Computed. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121215.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin, beta Subunit, Human; 0 / alpha-Fetoproteins
  •  go-up   go-down


32. Yang WP, Zou Y, Huang CS, Zhang SZ, Xiao Q, Dai KL, Zhong HS, Xiong XJ: [Clinicopathologic and prognostic study of pediatric immature teratoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Oct;36(10):666-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic and prognostic study of pediatric immature teratoma].
  • OBJECTIVE: To study the clinicopathologic features and biologic behavior of pediatric immature teratoma.
  • METHODS: The clinical data, pathologic features, immunohistochemical findings (for cyclin D1, P27 and Ki-67) and follow-up information of 39 cases of pediatric immature teratoma were analyzed.
  • RESULTS: Amongst the 39 cases studied, 12 arose in the sacrococcygeal region, 12 in testis, 5 in retroperitoneum, 4 in ovary, 4 in abdomen and 2 in mediastinum.
  • Immature neuroepithelial features used in histologic grading included the presence of primitive neural tubules, immature rosettes, undifferentiated neuroblastoma cells and primitive neuroectodermal structures.
  • The prognosis of immature teratoma in children is different from that in adults.
  • Sacrococcygeal immature teratoma occurring in patients younger than 1 year old and with low histologic grade do not require postoperative chemotherapy if the tumor is completely excised.
  • Similarly, for testicular immature teratoma occurring in patients below 1 year of age, regardless of tumor grading, need no adjunctive therapy.
  • On the other hand, ovarian immature teratoma with high histologic grade requires postoperative chemotherapy, regardless of age of the patients.
  • The presence of microscopic foci of yolk sac tumor is a useful predictor of recurrence in pediatric immature teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Retroperitoneal Neoplasms / pathology. Teratoma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cyclin D1 / metabolism. Endodermal Sinus Tumor / drug therapy. Endodermal Sinus Tumor / metabolism. Endodermal Sinus Tumor / pathology. Endodermal Sinus Tumor / surgery. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Ki-67 Antigen / metabolism. Male. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / metabolism. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / surgery. Neoplasm Recurrence, Local. Neoplasm Staging. Proliferating Cell Nuclear Antigen / metabolism. Sacrococcygeal Region. Survival Rate. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194599.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / alpha-Fetoproteins; 0 / p27 antigen; 136601-57-5 / Cyclin D1
  •  go-up   go-down


33. Mangili G, Scarfone G, Gadducci A, Sigismondi C, Ferrandina G, Scibilia G, Viganò R, Tateo S, Villa A, Lorusso D: Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol; 2010 Oct;119(1):48-52
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9).
  • OBJECTIVE: Conservative surgery followed by platinum-based chemotherapy is considered the standard approach for stage I immature ovarian teratoma (IT), except for stage IA G1.
  • Nevertheless the use of chemotherapy in stage IA G2-3 and IB-IC is controversial.
  • The aim of this study was to evaluate the outcome of patients with IT in order to define the role of chemotherapy in stage I disease.
  • Grade, stage, age, surgical and postoperative treatment were analyzed using χ(2) test and T test looking for association with recurrence.
  • Nine patients received adjuvant chemotherapy.
  • Overall recurrence rate was 21.4% (2 in chemotherapy group and 4 in the group without treatment).
  • Recurrence rate was not significantly different according to stage, grade or adjuvant chemotherapy, whereas it was greater in the group not operated in a MITO center, not staged and of age lower than 20 years, with statistical significance.
  • At recurrence 4 patients presenting with mature teratoma were treated with surgery alone, whereas 2 recurring with IT were treated with surgery plus chemotherapy.
  • CONCLUSIONS: Our study suggests that chemotherapy may be withheld for primary therapy and utilized only for recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Teratoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bleomycin / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20599258.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Karam JA, Raj GV: Growing teratoma syndrome. Urology; 2009 Oct;74(4):783-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome.
  • Physical examination revealed a right testicular tumor and CT scan showed a large retroperitoneal mass.
  • After 1 cycle of chemotherapy, CT scan showed interval enlargement of the retroperitoneal mass.
  • Percutaneous biopsy was consistent with teratoma.
  • The patient received 4 cycles of chemotherapy.
  • [MeSH-major] Teratoma. Testicular Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19647298.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Denaro L, Pluchinotta F, Faggin R, Manara R, Calderone M, Viscardi E, Gardiman M, Rossetto M, Perilongo G, d'Avella D: What's growing on? The growing teratoma syndrome. Acta Neurochir (Wien); 2010 Nov;152(11):1943-6
MedlinePlus Health Information. consumer health - Drug Reactions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What's growing on? The growing teratoma syndrome.
  • BACKGROUND: The growing teratoma syndrome (GTS) consists of a mature teratoma paradoxically enlarging during or after chemotherapy for malignant nongerminomatous germ cell tumors.
  • CONCLUSIONS: When normalized tumor markers after chemotherapy are associated with imaging features of a growing mass, the hypothesis of GTS must be taken in consideration.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Drug-Related Side Effects and Adverse Reactions. Neoplasms, Germ Cell and Embryonal / complications. Neoplasms, Germ Cell and Embryonal / drug therapy. Pinealoma / complications. Pinealoma / drug therapy. Teratoma / chemically induced
  • [MeSH-minor] Adolescent. Child, Preschool. Drug Therapy / methods. Humans. Male. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878531.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Hariprasad R, Kumar L, Janga D, Kumar S, Vijayaraghavan M: Growing teratoma syndrome of ovary. Int J Clin Oncol; 2008 Feb;13(1):83-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome of ovary.
  • Growing teratoma syndrome is an increase of tumor size containing only a mature teratoma component, during or after chemotherapy for germ cell tumors.
  • We describe three patients with malignant immature teratoma treated with chemotherapy and surgical resection.
  • All three had an increase in the size of the mass after chemotherapy, surgery was possible, and histology revealed mature teratoma.
  • One of the patients showed fluorodeoxy glucose positron emission tomography (FDG-PET) positivity for growing teratoma syndrome, but the histology revealed only mature teratoma.
  • Early recognition of this syndrome is essential as it offers hope for curative resection and avoids the use of ineffective chemotherapy.
  • [MeSH-major] Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1977 Dec;40(6):2987-92 [563283.001]
  • [Cites] Gynecol Oncol. 2006 Mar;100(3):608-11 [16226796.001]
  • [Cites] Eur Radiol. 2003 Sep;13(9):2115-8 [12928961.001]
  • [Cites] Gynecol Oncol. 1983 Dec;16(3):414-21 [6654184.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):395-9 [8314544.001]
  • [Cites] Obstet Gynecol. 1994 Oct;84(4 Pt 2):719-21 [9205463.001]
  • [Cites] Clin Radiol. 1991 Jun;43(6):402-8 [2070582.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):346-50 [65751.001]
  • [Cites] J Gynecol Obstet Biol Reprod (Paris). 1987;16(7):861-7 [3327877.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2004 Jun;44(3):268-9 [15191458.001]
  • [Cites] Gynecol Oncol. 1992 Jul;46(1):111-4 [1634130.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1311-4 [7540039.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):259-62 [14551755.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):2015-8 [6478436.001]
  • [Cites] Gynecol Oncol. 1994 Mar;52(3):287-91 [8157184.001]
  • [Cites] Gynecol Oncol. 2002 Mar;84(3):464-7 [11855890.001]
  • [Cites] J Obstet Gynaecol Res. 2002 Jun;28(3):166-71 [12214834.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):761-3 [16125758.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:384-90 [16515629.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):357-60 [14751185.001]
  • [Cites] Br J Urol. 1991 Feb;67(2):195-202 [2004236.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • (PMID = 18307026.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


37. Labarthe P, Khedis M, Chevreau C, Mazerolles C, Thoulouzan M, Durand X, Soulie M, Rischmann P, Plante P, Thonneau P, Houlgatte A, Huyghe E: [Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years]. Prog Urol; 2008 Dec;18(13):1075-81
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of pure teratoma of the testis in adult, results of a multicenter study over 15 years].
  • [Transliterated title] Prise en charge du tératome pur testiculaire postpubertaire à propos d'une série multicentrique sur 15 ans.
  • OBJECTIVE: To analyze cases of pure teratoma of the testis (PTT) of a large population-based study, as such tumors are rare, and to make an update on the topic.
  • PATIENTS AND METHODS: We retrospectively reviewed the records of patients treated for PTT from 1987 to 2003 in the French Midi-Pyrenees region (southwestern France) and in the Val-de-Grâce military hospital, Paris.
  • Among more than 1000 cases of testis cancer, we identified 20 cases of PTT (4% of the whole population).
  • For the localized PTT patients, four out of eight out of 8 were on surveillance only after the orchiectomy, and the remaining four received adjuvant chemotherapy.
  • All patients with the metastatic disease were treated by chemotherapy followed by surgical removal of residual tumor masses.
  • With a mean of 125 months follow-up, 85% of the population did not relapse after treatment.
  • [MeSH-major] Teratoma / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Prospective Studies. Time Factors. Young Adult

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041814.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] France
  •  go-up   go-down


38. Kume H, Kakutani S, Tomita K, Kitamura T: Salvage combination chemotherapy with docetaxel, ifosfamide and cisplatin (DIP): successful treatment of a case with metastatic testicular immature teratoma. Jpn J Clin Oncol; 2008 Feb;38(2):143-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage combination chemotherapy with docetaxel, ifosfamide and cisplatin (DIP): successful treatment of a case with metastatic testicular immature teratoma.
  • We present a case of metastatic testicular immature teratoma that was successfully treated despite resistance to standard chemotherapy and unsuccessful salvage surgery.
  • At first, BEP (bleomycin, etoposide and cisplatin) treatment was performed but failed.
  • By the time of the referral lung and mediastinal lymph node metastasis had appeared and para-aortic lymph node metastasis had grown larger.
  • We administered the DIP (docetaxel, ifosfamide and cisplatin) regimen as a second line chemotherapy, which was effective with 82% reduction of para-aortic lymph nodes, 88% of mediastinal lymph nodes and 85% of lung metastasis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Salvage Therapy / methods. Teratoma / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Humans. Ifosfamide / administration & dosage. Lymph Node Excision. Lymphatic Metastasis. Male. Mediastinum. Taxoids / administration & dosage. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250203.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


39. Milicevic S, Argirović R, Radunović N, Vilendecić Z, Plećas D, Pervulov M, Mirković L, Berisavac M, Bosković V: Two cases of immature teratoma with positive reproductive outcomes. Eur J Gynaecol Oncol; 2008;29(2):186-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of immature teratoma with positive reproductive outcomes.
  • The peak incidence of immature teratoma is in the early reproductive period of a woman's life and fertility preservation is an inevitable topic when discussing treatment options.
  • We present two cases of immature teratoma with positive reproductive outcome.
  • Bearing this in mind, the long-term effect of chemotherapy on ovarian function can be avoided and fertility, an important factor in the overall quality of life, can be preserved.
  • [MeSH-major] Ovarian Neoplasms / surgery. Ovariectomy. Teratoma / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459562.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Yoshioka M, Mori T, Okuma T, Kitamura N, Ito N, Nishi K: Mediastinal growing teratoma syndrome. Jpn J Thorac Cardiovasc Surg; 2000 Jan;48(1):66-8
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal growing teratoma syndrome.
  • A 27-year-old man had undergone orchiectomy and chemotherapy for testicular cancer.
  • Despite normalization of raised tumor marker levels after postoperative chemotherapy, computed tomographic scanning demonstrated multiple swellings of the para-aortic lymph nodes with extension from beneath the aortic arch to the bifurcation of the descending aorta.
  • The patient presented the typical features of mediastinal and retroperitoneal growing teratoma syndrome.
  • Histological examination of the resected specimens revealed a mature teratoma component without malignant cells.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Neoplasms, Second Primary. Teratoma / surgery
  • [MeSH-minor] Adult. Follow-Up Studies. Germinoma / drug therapy. Germinoma / surgery. Humans. Male. Orchiectomy. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery. Syndrome. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10714023.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


41. Hirasawa T: [Ovarian neuroendocrine carcinoma associated with mucinous carcinoma and teratoma]. Nihon Rinsho; 2004 May;62(5):973-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian neuroendocrine carcinoma associated with mucinous carcinoma and teratoma].
  • The former patient was not treated with chemotherapeutic therapy for her own initiative and died of the tumor extent ten months after surgery.
  • The latter patient has taken an uneventful clinical course for ten years after surgery with chemotherapy.
  • The therapeutic protocols including chemotherapy and irradiation have not been established yet.
  • In most ovarian NECs, histogenesis is considered to be associated with mucinous or teratoma tumor which coexists with NEC.

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15148829.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Kurata A, Hirano K, Nagane M, Fujioka Y: Immature teratoma of the ovary with distant metastases: favorable prognosis and insights into chemotherapeutic retroconversion. Int J Gynecol Pathol; 2010 Sep;29(5):438-44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immature teratoma of the ovary with distant metastases: favorable prognosis and insights into chemotherapeutic retroconversion.
  • We present a case of a young woman with an immature teratoma of the right ovary that showed systemic metastases.
  • Pathologic diagnosis was an immature teratoma, grade 2.
  • As brain, lung, and liver metastases were discovered within 2 years after the operation, sequential resections of the metastatic foci were performed before chemotherapy as well as during the early and late stages of chemotherapy.
  • The resected specimens of each metastatic focus contained histologically more mature elements of the primary immature teratoma and exhibited a decrease in the Ki-67 labeling index, the later the resection was performed.
  • As far as we know, this is the first case of brain metastasis stemming from an immature teratoma of the ovary.
  • In addition, it was highly suggestive that chemotherapy itself was the main etiological factor for the promotion of maturation.
  • [MeSH-major] Ovarian Neoplasms / pathology. Teratoma / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736769.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


43. Le Goarant de Tromelin J, Deruelle P, Lucot JP, Collinet P, Cosson M, Vinatier D: [Strategy for management of ovarian immature teratoma. About three cases and review]. Gynecol Obstet Fertil; 2005 Sep;33(9):594-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Strategy for management of ovarian immature teratoma. About three cases and review].
  • [Transliterated title] Evaluation de la prise en charge des tératomes immatures de l'ovaire. A propos de trois cas et revue de la littérature.
  • Ovarian immature teratoma is a malignant germ cell tumor and represents less than 1% of ovarian malignant tumors.
  • Tissues are derived from the three germ layers (endo-, meso- and ectoderm).
  • Therapeutic management is balanced between adjuvant chemotherapy and surgery alone.
  • Nevertheless, as immature teratoma mostly occurs in young women, the main objective is to preserve fertility.
  • [MeSH-major] Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / surgery. Teratoma / drug therapy. Teratoma / surgery

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217865.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 40
  •  go-up   go-down


44. Lee SH, Lee KB, Shin JW, Chung DH, Park CY: Ovarian malignant melanoma without evidence of teratoma. J Obstet Gynaecol Res; 2010 Aug;36(4):898-901
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian malignant melanoma without evidence of teratoma.
  • Extensive debulking surgery was performed and chemotherapy was given.
  • Microscopically, no evidence of other accompanying tumor, such as teratoma was noted.
  • Despite the surgery and chemotherapy, the patient died within 2 months of diagnosis.
  • Considering this case, it is assumed that the combination of surgical debulking and chemotherapy are not always beneficial in ovarian malignant melanoma and the prognosis of ovarian malignant melanoma is very poor.

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20666966.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


45. Gorbatiy V, Spiess PE, Pisters LL: The growing teratoma syndrome: Current review of the literature. Indian J Urol; 2009 Apr;25(2):186-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growing teratoma syndrome: Current review of the literature.
  • Growing teratoma syndrome (GTS) is a rare condition among patients with non-seminomatous germ cell tumors who present with enlarging metastatic masses during appropriate systemic chemotherapy and in the context of normalized serum markers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Dec;31(12):1913-8 [18043048.001]
  • [Cites] Eur J Cancer. 2000 Jul;36(11):1389-94 [10899652.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:384-90 [16515629.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):942-7 [9307195.001]
  • [Cites] Eur Urol. 1997;32(3):305-9 [9358218.001]
  • [Cites] Urol Int. 1995;55(4):226-8 [8588272.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):56-60 [8289455.001]
  • [Cites] Gynecol Oncol. 1993 Jun;49(3):395-9 [8314544.001]
  • [Cites] Br J Urol. 1991 Feb;67(2):195-202 [2004236.001]
  • [Cites] Eur J Cancer Clin Oncol. 1989 Dec;25(12):1739-43 [2483686.001]
  • [Cites] Br J Cancer. 1984 Nov;50(5):611-6 [6498061.001]
  • [Cites] Pediatr Radiol. 2004 Mar;34(3):259-62 [14551755.001]
  • [Cites] Cancer. 2007 Dec 15;110(12):2700-8 [17948916.001]
  • [Cites] Cancer. 1982 Oct 15;50(8):1629-35 [6288220.001]
  • [Cites] J Urol. 1981 Jul;126(1):52-4 [7253077.001]
  • [Cites] Obstet Gynecol. 1977 Mar;49(3):346-50 [65751.001]
  • [Cites] Cancer. 1977 Dec;40(6):2987-92 [563283.001]
  • [Cites] Lancet. 1969 Nov 1;2(7627):949-52 [4186609.001]
  • [Cites] Lancet. 1975 Jan 4;1(7897):43-4 [46367.001]
  • [Cites] J Urol. 1973 Jul;110(1):90-2 [4713368.001]
  • [Cites] Am J Clin Pathol. 1973 Mar;59(3):338-43 [4687350.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):357-60 [14751185.001]
  • [Cites] Eur Radiol. 2003 Sep;13(9):2115-8 [12928961.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4494-6 [17906212.001]
  • (PMID = 19672343.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2710061
  • [Keywords] NOTNLM ; Enlarging metastatic mass / growing teratoma / non-seminatous germ cell tumors
  •  go-up   go-down


46. Loy V, Klenk U, Linke J: [Regression of germ cell tumors after chemotherapy]. Pathologe; 2004 Nov;25(6):469-73
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of germ cell tumors after chemotherapy].
  • [Transliterated title] Regression von Keimzelltumoren nach Chemotherapie.
  • Today the treatment of gonadal germ cell tumors is standardized.
  • The cisplatin containing chemotherapy and the multi-modal therapy strategies have increased the rate of successful treatment enormously.
  • Following the rare, primary chemotherapy, the residual tumor must be classified according to the WHO as accurately as possible.
  • The examination of the tissue samples from a retroperitoneal lymphadenectomy after chemotherapy is problematic.
  • Is there still vital tumor present then it can most often be diagnosed as a teratoma.
  • If a tissue sample contains other differentiations, the classification is performed in detail according to the WHO classification of germ cell tumors.
  • Sarcomas or carcinomas must be reliably distinguished and classified, as they lead to different therapeutic consequences.
  • [MeSH-major] Germinoma / drug therapy. Germinoma / pathology. Ovarian Neoplasms / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1981 Sep;41(9 Pt 1):3275-80 [6167346.001]
  • [Cites] Urologe A. 1998 Nov;37(6):625-8 [9887491.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Cancer. 1987 Feb 1;59(3):533-9 [3024806.001]
  • [Cites] Eur Urol. 2001 Oct;40(4):372-91 [11713391.001]
  • [Cites] J Urol. 1997 May;157(5):1705-9; discussion 1709-10 [9112510.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):148-56 [1688399.001]
  • [Cites] Br J Cancer. 1994 Nov;70(5):960-5 [7524606.001]
  • [Cites] Am J Surg Pathol. 1988 Jul;12(7):531-41 [3291625.001]
  • [Cites] Urologe A. 2002 Jul;41(4):374-85; quiz 386-7 [12214458.001]
  • [Cites] Eur Urol. 2004 May;45(5):564-73 [15082197.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:1-11 [14184707.001]
  • [Cites] J Urol. 1982 Aug;128(2):315-20 [7109099.001]
  • [Cites] J Urol. 1994 Oct;152(4):1144-9 [8072083.001]
  • [Cites] Eur Urol. 1999 Dec;36(6):601-8 [10559615.001]
  • [Cites] Semin Urol Oncol. 2002 Nov;20(4):262-71 [12489059.001]
  • [Cites] Urologe A. 1998 Nov;37(6):621-4 [9887490.001]
  • [Cites] J Urol. 1990 Aug;144(2 Pt 1):287-91; discussion 291-2 [2165181.001]
  • [Cites] World J Urol. 1994;12(4):196-9 [7820141.001]
  • (PMID = 15549315.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Lukaszewski T, Połczyńska-Kaniak E, Puacz P, Seremak-Mrozikiewicz A, Drews K: [Sacrococcygeal teratoma in foetus--case report]. Ginekol Pol; 2009 Nov;80(11):861-4
MedlinePlus Health Information. consumer health - Birth Defects.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sacrococcygeal teratoma in foetus--case report].
  • Sacrococcygeal teratoma develops from all three germinal layers (endoderm, mesoderm and ectoderm).
  • Sacrococcygeal teratomas (SCT) are the most common neoplasms in the fetus and newborns, with an estimated prevalence of 1 in 20,000 to 1 in 40,000.
  • According to Polish Gynecology Society Recommendation, the main aim of intrauterine intervention or pharmacological treatment in case of prenatally diagnosed SCT is to prevent development of severe fetal cardiac failure.
  • The following article describes a case report of a 34-year-old pregnant woman, 23 weeks of gestation, with a diagnosis of fetal sacrococcygeal teratoma.
  • [MeSH-major] Abortion, Eugenic. Congenital Abnormalities / diagnostic imaging. Sacrococcygeal Region / diagnostic imaging. Spinal Neoplasms / diagnostic imaging. Teratoma / diagnostic imaging

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088402.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


48. Mourali M, Ben Haj Hassine A, El Fekih C, Essoussi-Chikhaoui J, Binous N, Ben Zineb N, Ayadi M, Mezni F: [Immature teratoma of the ovary and pregnancy]. Tunis Med; 2010 Jul;88(7):507-12
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immature teratoma of the ovary and pregnancy].
  • [Transliterated title] Tératome Immature De L'ovaire Et Grossesse.
  • BACKGROUND: Composing of less than 1% of all ovarian cancers, immature teratoma is a malignancy that mainly affects the young.
  • Immature teratoma of the ovary together with pregnancy is rare.
  • AIM: We Report two cases of immature teratoma of the ovary diagnosed during pregnancy and their respective issue.
  • A 28 years old woman gravida 1 with an immature teratoma of the ovary discovered during delivery by caesarean section.
  • The treatment was conservative including salpingo-oophorectomy, omentectomy, aortic lymph node dissection and appendectomy.
  • She delivered by caesarean section in order to perform radical treatment: hysterectomy and oophorectomy of the remaining ovary. 2nd case.
  • A conservative treatment was indicated, including salpingo-oophorectomy, omentectomy, aortic lymph node dissection, appendectomy and biopsy of the remaining ovary.
  • CONCLUSION: Immature teratoma is graded from 1 to 3.
  • Conservative treatment without associating chemotherapy can be tempted in tumours with a stade AI and a low grade.
  • [MeSH-major] Pregnancy Complications, Neoplastic. Teratoma

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582889.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


49. Brandli DW, Ulbright TM, Foster RS, Cummings OW, Zhang S, Sweeney CJ, Eble JN, Cheng L: Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res; 2003 Sep 15;63(18):6063-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma.
  • Metastatic mature teratoma is often present in postchemotherapy surgical specimens of lymph nodes from patients with pathological stage II or III testicular germ cell tumors.
  • The stromal cells in these lesions have generally been considered "fibrosis" secondary to the chemotherapy and the necrosis it causes, although the frequent cytological atypia of the stromal cells suggests that they may be neoplastic.
  • We studied 25 patients with pathological stage II or III testicular cancer who were treated with platinum-based chemotherapy followed by surgical resection of retroperitoneal lymph nodes that contained metastatic mature teratoma with "fibrosis" to determine the reactive or neoplastic nature of the stromal cells.
  • We compared the pattern of allelic loss using nine microsatellite DNA markers (D9S177, D9S303, D9S778, D9S171, D12S1015, D1S508, D2S156, D18S46, and D11S903) between the epithelial cells of the teratoma and the cells in the adjacent stroma.
  • A laser capture microdissection technique facilitated preparation of genomic DNA from the epithelial components of teratoma, adjacent stromal cells, and normal lymph node tissue from each patient.
  • Of the 25 patients, loss of heterozygosity was seen at a minimum of one focus in 22 (92%) of the teratoma specimens and 16 (64%) of the adjacent stroma.
  • Of the 16 cases for which the stroma showed loss of heterozygosity, 8 cases showed the identical pattern of allelic loss in the epithelial cells of the adjacent teratoma at all nine DNA loci studied.
  • Interestingly, three cases showed loss of heterozygosity in the stroma that was not seen in the matching teratoma specimens.
  • Our results indicate that the stromal cells adjacent to metastatic mature teratoma in postchemotherapy lymph node specimens frequently have genetic abnormalities similar to the metastatic teratoma.
  • Concordant genetic alterations observed in teratoma and stroma suggest that both are derived from the same element of the original germ cell tumor or the same progenitor cell.
  • [MeSH-major] Neoplastic Stem Cells / pathology. Teratoma / genetics. Teratoma / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14522936.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Elli M, Pinarli FG, Kandemir B, Dagdemir A, Ceyhan M, Acar S: Sacrococygeal teratoma with sarcomatous differentiation in a child. Pediatr Hematol Oncol; 2008 Jun;25(4):345-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sacrococygeal teratoma with sarcomatous differentiation in a child.
  • Most of the extragonadal teratomas are located in the sacrococygeal region.
  • Teratoma with malignant sarcomatous differentiation is a rare form of germ cell tumor.
  • The authors describe a 5-year-old-girl with sacrococygeal teratoma in which sarcomatous elements were observed.
  • The patient was treated with complete surgical excision and adjuvant chemotherapy according to sarcoma protocols.
  • [MeSH-major] Sacrococcygeal Region. Sarcoma / pathology. Soft Tissue Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Actins / analysis. Child, Preschool. Combined Modality Therapy. Dactinomycin / therapeutic use. Female. Humans. Magnetic Resonance Imaging. Vimentin / analysis. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18484480.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Vimentin; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


51. Beiner ME, Gotlieb WH, Korach Y, Shrim A, Stockheim D, Segal Y, Fridman E, Ben-Baruch G: Cystectomy for immature teratoma of the ovary. Gynecol Oncol; 2004 May;93(2):381-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystectomy for immature teratoma of the ovary.
  • Because of the excellent response to chemotherapy, the standard of care is unilateral salpingo-oophorectomy (USO), but some patients undergo cystectomy only before final pathology.
  • In view of the lack of information concerning the outcome following cystectomy in germ cell tumors, we retrospectively evaluated the clinical outcome of patients who underwent cystectomy only as part of their surgical treatment.
  • RESULTS: All the eight patients who underwent cystectomy were diagnosed with immature teratoma (three grade 1, four grade 2, and one grade 3) on final pathology following surgery.
  • All except three patients (two with grade 1 and one with grade 2 disease) received adjuvant chemotherapy.
  • CONCLUSIONS: Cystectomy followed by adjuvant chemotherapy appeared satisfactory for apparent early-stage immature teratoma when close follow-up was carried out.
  • [MeSH-major] Ovarian Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures / methods. Humans. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099949.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Lam CM, Yu VS: SIADH associated with ovarian immature teratoma: a case report. Eur J Gynaecol Oncol; 2004;25(1):107-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIADH associated with ovarian immature teratoma: a case report.
  • Immature teratoma in association with SIADH is rare.
  • Subsequent investigation confirmed SIADH and grade 2 ovarian immature teratoma.
  • No other causes of SIADH were found apart from the immature teratoma.
  • There was no further recurrence of SIADH after the curative surgery and chemotherapy.
  • We postulate that immature teratoma consists of neurohypophyseal structures which account for the ADH release.
  • [MeSH-major] Inappropriate ADH Syndrome / diagnosis. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053076.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Jung CK, Lee YS, Jung ES, Kang CS, Kim BK: Oligodendroglioma arising in a sacrococcygeal immature teratoma. J Korean Med Sci; 2002 Jun;17(3):426-8
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglioma arising in a sacrococcygeal immature teratoma.
  • Tumors of neuroepithelial origin are extremely rare in teratoma and tend to be derived from glial or primitive neuroectodermal cells.
  • We describe a case of 2- month-old baby girl with an oligodendroglioma arising in an immature teratoma of the sacrococcygeal region.
  • Because immature teratoma was grade II, the patient received adjuvant chemotherapy.
  • [MeSH-major] Oligodendroglioma / pathology. Sacrococcygeal Region / pathology. Spinal Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068154.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3054871
  •  go-up   go-down


54. Newsom-Davis T, Poulter D, Gray R, Ameen M, Lindsay I, Papanikolaou K, Butler-Manuel S, Christmas T, Townsend P, Seckl M: Case report: malignant teratoma of the uterine corpus. BMC Cancer; 2009;9:195
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: malignant teratoma of the uterine corpus.
  • BACKGROUND: Teratomas are the commonest germ cell tumours and are most frequently found in the testes and ovary.
  • Extragonadal teratomas are rare and mainly occur in midline structures.
  • Uterine teratomas are extremely rare with only a few previous case reports, usually involving mature teratomas of the uterine cervix.
  • Initial investigations revealed a benign teratoma of the uterus which was removed.
  • Her symptoms persisted and a recurrent, now malignant, teratoma of the uterine corpus was resected at hysterectomy.
  • Six months after surgery she relapsed with para-aortic lymphadenopathy and was treated with a taxane, etoposide and cisplatin-containing chemotherapy regimen followed by retroperitoneal lymph node dissection.
  • CONCLUSION: In this report we discuss the aetiology, diagnosis and management of uterine teratomas, and review previous case studies.
  • [MeSH-major] Teratoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymphatic Diseases / etiology. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 May;53(5):327-31 [12713570.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1169-75 [15026797.001]
  • [Cites] Obstet Gynecol. 1972 Nov;40(5):686-91 [5083218.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Histopathology. 1979 Jul;3(4):339-45 [468134.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):106-10 [3988122.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Oct;77(9):936-8 [9808385.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):216-8 [15972426.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Apr;29(4):477-8 [17330830.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):293-6 [17630116.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):43-50 [17466047.001]
  • [Cites] Kurume Med J. 1993;40(3):153-8 [8139215.001]
  • (PMID = 19538751.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2709639
  •  go-up   go-down


55. Winter C, Raman JD, Sheinfeld J, Albers P: Retroperitoneal lymph node dissection after chemotherapy. BJU Int; 2009 Nov;104(9 Pt B):1404-12
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal lymph node dissection after chemotherapy.
  • Retroperitoneal lymph node dissection after chemotherapy (PC-RPLND) plays a crucial role in managing patients with advanced germ cell tumours (GCTs).
  • In the last few years improvements in radiographic staging, a better understanding of the role of serum tumour markers, and the introduction of cisplatin-based chemotherapy have all contributed to this surgical therapy.
  • PC-RPLND is necessary when residual radiographic abnormalities are present after chemotherapy.
  • The need for a PC-RPLND in the face of normal findings from computed tomography (CT) is controversial.
  • CT criteria alone are not sufficiently reliable to distinguish viable tumour or teratoma from necrosis.
  • No combination of variables can predict negative retroperitoneal pathology with sufficient accuracy after induction chemotherapy.
  • Unresected teratoma or viable GCT are at least partly chemorefractory and, if untreated, will progress.
  • In PC-RPLND surgical margins should not be compromised in an attempt to preserve ejaculation, although nerve-sparing dissections are possible in patients with marker normalization after chemotherapy and necrotic tissue in frozen-section histology.
  • The size and location of residual masses coupled with the retroperitoneal desmoplastic reaction make PC-RPLND a technically demanding procedure that should be performed by experienced surgeons in dedicated referral centres.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Node Excision / methods. Neoplasms, Germ Cell and Embryonal / surgery. Retroperitoneal Neoplasms / surgery. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Ejaculation. Humans. Lymphatic Metastasis. Male. Orchiectomy. Positron-Emission Tomography. Predictive Value of Tests. Sexual Dysfunction, Physiological / etiology. Teratoma / secondary. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19840021.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 120
  •  go-up   go-down


56. Schmidt D, Kommoss F: [Teratoma of the ovary. Clinical and pathological differences between mature and immature teratomas]. Pathologe; 2007 May;28(3):203-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Teratoma of the ovary. Clinical and pathological differences between mature and immature teratomas].
  • [Transliterated title] Teratome des Ovars. Klinisch-pathologische Unterschiede zwischen unreifen und reifen Teratomen.
  • Teratomas are the most frequent germ cell tumors of the ovary.
  • Two main groups can be distinguished: mature and immature teratomas.
  • Mature teratomas are benign tumors, which are most often composed of derivatives of two or three germ cell layers.
  • In contrast, immature teratomas are malignant ovarian tumors.
  • They contain immature tissue elements in addition to the mature components, most often consisting of immature neural tissue.
  • The proportion of immature tissue elements defines the grade of immaturity.
  • Grade 0 represents a mature teratoma.
  • With the exception of childhood cases, grade 2 and 3 immature teratomas are treated with chemotherapy.
  • If a focus of YST is present, the patient is treated with chemotherapy.
  • Both in cases of mature and immature teratoma, peritoneal implants can be found (gliomatosis peritonei), which are also graded.
  • In cases of immature peritoneal implants, patients are also treated with chemotherapy.
  • Gliomatosis peritonei is most likely derived from metaplasia of subperitoneal stem cells; it does not represent a metastatic disease of the ovarian teratoma.
  • [MeSH-major] Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1978 Aug;102(8):420-5 [580884.001]
  • [Cites] Pathol Res Pract. 1989 Apr;184(4):422-30 [2726609.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):685-8 [15188134.001]
  • [Cites] Mod Pathol. 2006 Jun;19(6):766-71 [16547466.001]
  • [Cites] Mod Pathol. 1997 Jun;10(6):597-601 [9195578.001]
  • [Cites] Am J Surg Pathol. 1998 Sep;22(9):1115-24 [9737245.001]
  • [Cites] Am J Surg Pathol. 1993 Aug;17(8):764-78 [8393302.001]
  • [Cites] Klin Padiatr. 2006 Nov-Dec;218(6):296-302 [17080330.001]
  • [Cites] J Clin Pathol. 1983 Jan;36(1):68-73 [6822679.001]
  • [Cites] Int J Oncol. 2004 Jul;25(1):17-25 [15201985.001]
  • [Cites] Int J Gynecol Pathol. 2005 Apr;24(2):173-82 [15782074.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):263-71 [10811491.001]
  • [Cites] Am J Obstet Gynecol. 1946 Feb;51:151-72 [21012750.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S61-79 [15761467.001]
  • [Cites] APMIS. 2003 Jan;111(1):152-60; discussion 160 [12752256.001]
  • [Cites] Am J Obstet Gynecol. 1999 Aug;181(2):353-8 [10454682.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):82-5 [11781530.001]
  • [Cites] Cancer. 1976 May;37(5):2359-72 [1260722.001]
  • (PMID = 17396268.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


57. Carver BS, Bianco FJ Jr, Shayegan B, Vickers A, Motzer RJ, Bosl GJ, Sheinfeld J: Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection. J Urol; 2006 Jul;176(1):100-3; discussion 103-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection.
  • PURPOSE: The biological potential of teratoma remains unpredictable, therefore identifying its presence in the retroperitoneum remains important.
  • We evaluated patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous germ cell tumors to determine predictors of teratomatous elements in the retroperitoneum.
  • MATERIALS AND METHODS: We identified 532 patients from 1989 to 2003 who underwent retroperitoneal lymph node dissection following chemotherapy for nonseminomatous germ cell tumors at our institution.
  • RESULTS: Of the 532 patients in our series 450 (85%) received only induction chemotherapy and 82 (15%) required salvage chemotherapy.
  • Retroperitoneal nodal pathology revealed teratomatous elements in 235 (44%) patients and only teratoma in 210 (40%) patients.
  • By multivariate analysis testicular yolk sac tumor (p = 0.046), teratoma in the orchiectomy specimen (p <0.005), relative change in nodal size before and after chemotherapy (p <0.005), and no requirement for salvage chemotherapy (p = 0.03) were independent predictors for the presence of teratoma in the retroperitoneum.
  • CONCLUSIONS: Teratoma remains a common histological finding in the retroperitoneal lymph nodes following chemotherapy.
  • We have identified several pre-retroperitoneal lymph node dissection variables that predict the finding of teratoma in the retroperitoneum for men treated with chemotherapy for metastatic nonseminomatous germ cell tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymph Node Excision. Teratoma / secondary. Testicular Neoplasms / pathology
  • [MeSH-minor] Humans. Logistic Models. Lymphatic Metastasis. Male. Multivariate Analysis. Retroperitoneal Space. Salvage Therapy

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753380.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


58. Jin FM, Zhu GZ, Feng YJ: [Clinical features and prognostic factors of malignant ovarian teratoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug;25(4):427-30
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic factors of malignant ovarian teratoma].
  • OBJECTIVE: To assess the clinical features and prognostic factors of malignant ovarian teratoma.
  • METHODS: Eighty-four patients with malignant ovarian teratoma between 1954 and 2001 were studied retrospectively.
  • Patient characteristics, surgical therapy, pathologic diagnosis, histological grade, and follow-up data were extracted and survival curves were depicted.
  • Thirty-seven women were diagnosed with malignant transformation of ovarian teratoma while 47 were of ovarian immature teratoma.
  • Five-year survival rate of malignant ovarian teratoma with stage I, II, III, and IV were (87.20 +/- 4.52)%, (50.00 +/- 35.36)%, (30.55 +/- 9.43)%, and 0.00%, respectively (P = 0.00).
  • Five-year survival rate of ovarian immature teratoma with histological grade I, II, and III were (90.48 +/- 6.41)%, (68.75 +/- 11.59)%, and (57.14 +/- 16.38)%, respectively (P = 0.08).
  • Among 31 women died of malignant ovarian teratoma, 27 (87.1%) died within 2 years after operation.
  • CONCLUSION: This retrospective study suggests that malignant transformation of ovarian teratoma is clinically different from ovarian immature teratoma.
  • Complete staging surgery or Debulking surgery followed by 4-6 courses adjuvant chemotherapy with cisplatin, vincristine, and bleomycin are the principle treatment.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Hysterectomy. Male. Middle Aged. Neoplasm Staging. Ovariectomy. Prognosis. Retrospective Studies. Survival Rate. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12974088.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Leandros E, Alexakis N, Konstadoulakis M, Albanopoulos K, Dikoglou C, Bramis J: Postchemotherapy resection of a primary mature malignant retroperitoneal teratoma in an adult: report of a case. Surg Today; 2005;35(11):965-7
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postchemotherapy resection of a primary mature malignant retroperitoneal teratoma in an adult: report of a case.
  • We herein report a rare case of a 47-year-old man with a primary mature retroperitoneal malignant teratoma.
  • The patient received neoadjuvant chemotherapy and the residual tumor was resected.
  • A histopathological examination confirmed the diagnosis of malignant teratoma with endodermal, ectodermal, and mesenchymal structures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Retroperitoneal Neoplasms / surgery. Teratoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Apr 15;97(8):1869-75 [12673712.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):594-603 [9053482.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:265-72 [12401700.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2500-4 [9667270.001]
  • [Cites] J Clin Oncol. 2002 Apr 1;20(7):1864-73 [11919246.001]
  • [Cites] N Engl J Med. 1987 Jun 4;316(23):1435-40 [2437455.001]
  • [Cites] Surg Today. 1997;27(3):282-4 [9068117.001]
  • (PMID = 16249853.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


60. Itani Y, Kawa M, Toyoda S, Yamagami K, Hiraoka K: Growing teratoma syndrome after chemotherapy for a mixed germ cell tumor of the ovary. J Obstet Gynaecol Res; 2002 Jun;28(3):166-71
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome after chemotherapy for a mixed germ cell tumor of the ovary.
  • A retroperitoneal enlarging mass was detected and resected in a 24-year-old nulliparous woman after fertility-preserving surgery and adjuvant chemotherapy for a malignant germ cell tumor (MGCT) of the right ovary.
  • This enlarging mass contained only a mature teratoma component.
  • Alpha-fetoprotein, which was elevated to 21236.6 ng/mL before the initial surgery, persisted within normal after the completion of adjuvant platinum-based chemotherapy.
  • The patient was diagnosed with growing teratoma syndrome.
  • Growing teratoma syndrome originating from ovarian germ cell tumor is very rare.
  • Surgical resection and histological confirmation of growing mass after MGCT treatment is essential before conducting salvage chemotherapy.
  • [MeSH-major] Germinoma / surgery. Neoplasms, Second Primary / surgery. Ovarian Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Syndrome. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214834.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


61. Li H, Hong W, Zhang R, Wu L, Liu L, Zhang W: Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma. Chin Med J (Engl); 2002 Oct;115(10):1496-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma.
  • OBJECTIVE: To investigate the development regularity, treatment methods and prognosis of ovary immature teratoma (POIT).
  • From the 1980s, this was followed by four-cycles of combination chemotherapy (VAC, PVB or BEP x 3 cycles) as post-operative adjuvant therapy.
  • Combined chemotherapy and multiple operations were performed for advanced and recurrent lesions.
  • The chief prognostic factors for this disease are clinical stage, pathological grade and adequate treatment.
  • It is characterized by the fact that recurrent tumors may be converted back to mature ones as time goes on.
  • With chemotherapy, these is a good opportunity to rescue those patients with recurrent tumors.
  • At present, treatment of POIT gives the most satisfactory results among all malignant ovarian germ cell tumor types.
  • Tests of serum specific tumor markers (CA19-9, AFP, CA125, CEA) performed preoperatively or before chemotherapy and during follow-up have been found helpful in the evaluation of prognosis.
  • [MeSH-major] Ovarian Neoplasms / mortality. Teratoma / mortality

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490095.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


62. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.
  • A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension.
  • Loose myxoid tissue resembled primitive cartilage.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / diagnosis. Sarcoma / diagnosis. Teratoma / diagnosis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down


63. Amsalem H, Nadjari M, Prus D, Hiller N, Benshushan A: Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature. Gynecol Oncol; 2004 Jan;92(1):357-60
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growing teratoma syndrome vs chemotherapeutic retroconversion: case report and review of the literature.
  • BACKGROUND: Immature ovarian teratoma is the third most common germ cell tumor (GCT) following dysgerminoma and endodermal sinus tumor.
  • The treatment of choice during childbearing age for immature teratoma composes of unilateral oophorectomy and in case of metastatic disease postoperative chemotherapy (BEP).
  • Latter, Logothetis described what seems to be a similar phenomenon in testicular non-seminomatous germ cell tumor (NSGCT) that he called the "growing teratoma syndrome".
  • CASE: We present a case of a 12-year-old girl treated for growing teratoma syndrome after primary ovarian GCT.
  • [MeSH-major] Abdominal Neoplasms / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology. Pelvic Neoplasms / secondary. Teratoma / drug therapy. Teratoma / secondary

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14751185.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 14
  •  go-up   go-down


64. Uzunlar AK, Yalinkaya A, Yaldiz M, Kilinç N, Gül T: Survival and reproductive function after treatment of immature ovarian teratoma. Eur J Gynaecol Oncol; 2001;22(5):384-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and reproductive function after treatment of immature ovarian teratoma.
  • We conducted a clinical and pathologic review of nine patients with immature ovarian teratoma.
  • Low stage and low grade immature ovarian teratomas have an excellent prognosis.
  • Platinum-based chemotherapy has been confirmed to be effective in the management of patients with ovarian germ cell tumors.
  • Low grade pure ovarian immature teratoma is a potentially curable disease and a fertility-sparing surgical approach is possible.
  • [MeSH-major] Fertility. Ovarian Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11766747.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


65. Moiyadi A, Jalali R, Kane SV: Intracranial growing teratoma syndrome following radiotherapy--an unusually fulminant course. Acta Neurochir (Wien); 2010 Jan;152(1):137-42
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for growing teratoma syndrome .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial growing teratoma syndrome following radiotherapy--an unusually fulminant course.
  • INTRODUCTION: Residual radiologically progressive masses following multimodality treatment of malignant mixed intracranial germ cell tumors are described.
  • Often these enlarge, and this is called the growing teratoma syndrome.
  • RESULTS: A review of the scanty tissue was suggestive of a pineal parenchymal tumor, and hence radiation was planned.
  • After just ten fractions, he developed rapid neurological deterioration.
  • Histology revealed a purely mature teratoma.
  • CONCLUSION: Though a growing teratoma syndrome has been described following chemotherapy, no such report while on radiation exists.
  • [MeSH-major] Brain Neoplasms / etiology. Neoplasms, Radiation-Induced. Pinealoma / radiotherapy. Teratoma / etiology
  • [MeSH-minor] Child, Preschool. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404574.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Austria
  • [Number-of-references] 23
  •  go-up   go-down


66. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL: Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer; 2009 Mar 15;115(6):1310-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
  • BACKGROUND: Patients with pure teratoma within the postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimen traditionally have been considered at low risk for disease progression.
  • The objectives of this study were to determine the disease-related outcomes of patients who had pure teratoma identified at the time of PC-RPLND and to examine the prognostic value of clinical variables that were identified previously as important predictors of disease recurrence in these patients.
  • METHODS: Between 1980 and 2003, 97 patients with metastatic nonseminomatous germ cell tumor and pure teratoma histology at the time of PC-RPLND were identified.
  • The medical records of these patients were reviewed retrospectively for pertinent clinical and treatment-related outcomes.
  • RESULTS: At a median follow-up of 7.4 years, 21 patients (22%) developed recurrent disease after PC-RPLND.
  • Nine of 97 patients (9.3%) died from testis cancer, and 4 patients died from other causes.
  • CONCLUSIONS: In patients with pure teratoma histology at PC-RPLND, mediastinal involvement at presentation and the presence of an elevated AFP level before PC-RPLND predicted an unfavorable outcome.
  • Patients who had teratoma at the time of PC-RPLND remained at considerable risk for disease progression because of the unpredictable nature of teratoma and the presence of unrecognized, active germ cell disease outside the retroperitoneum.
  • [MeSH-major] Lymph Node Excision. Lymphatic Metastasis. Retroperitoneal Neoplasms / secondary. Teratoma / drug therapy. Teratoma / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Disease Progression. Humans. Male. Prognosis. Recurrence. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [CommentIn] Cancer. 2009 Mar 15;115(6):1138-41 [19165804.001]
  • (PMID = 19156903.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


67. Hanna A, Edan C, Heresbach N, Ben Hassel M, Guegan Y: [Expanding mature pineal teratoma syndrome. Case report]. Neurochirurgie; 2000 Dec;46(6):568-572
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expanding mature pineal teratoma syndrome. Case report].
  • We present a case of growing teratoma syndrome of the pineal region.
  • After three cycles of chemotherapy, MRI showed an important increase in tumor size with morphologic modifications.
  • Surgical resection was performed and histological examination of the whole specimen showed mature teratoma.
  • Growing teratoma syndrome is a mixed germ cell tumor with a secreting portion that responds to chemotherapy and a non secreting portion of mature teratoma that continues to grow under chemotherapy.
  • The treatment should include chemotherapy for the malignant secreting portion and surgery for the mature teratoma.
  • [MeSH-major] Pinealoma / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cerebrospinal Fluid Shunts. Chorionic Gonadotropin / blood. Chorionic Gonadotropin / cerebrospinal fluid. Chorionic Gonadotropin / secretion. Combined Modality Therapy. Diagnosis, Differential. Diplopia / etiology. Etoposide / administration & dosage. Germinoma / diagnosis. Humans. Ifosfamide / administration & dosage. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Proteins / blood. Neoplasm Proteins / cerebrospinal fluid. Neoplasm Proteins / secretion. Radiotherapy, Adjuvant. Remission Induction. Thalamus / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11148410.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chorionic Gonadotropin; 0 / Neoplasm Proteins; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


68. Hsieh YL, Liu CS: Progression from an immature teratoma with miliary gliomatosis peritonei to growing teratoma syndrome with nodular gliomatosis peritonei. Pediatr Neonatol; 2009 Apr;50(2):78-81
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression from an immature teratoma with miliary gliomatosis peritonei to growing teratoma syndrome with nodular gliomatosis peritonei.
  • A 4 1/2-year-old girl presented with an incompletely resected, huge, immature abdominal teratoma, elevated serum alpha-fetoprotein (AFP), and numerous miuiary gliomatosis peritonei (GP).
  • Two courses of chemotherapy resulted in normalization of her AFP level and marked tumor shrinkage.
  • Further chemotherapy was interrupted by complications.
  • During treatment for these complications, ascites increased and the tumor enlarged, but serum AFP remained within the normal range.
  • Second-took surgery revealed that the tumor had changed histologically to a mature teratoma, and GP had enlarged to nodular size, causing massive ascites.
  • The still incompletely resected, growing mature teratoma was reduced with interferon.
  • [MeSH-major] Glioma / pathology. Peritoneal Neoplasms / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453084.001).
  • [ISSN] 1875-9572
  • [Journal-full-title] Pediatrics and neonatology
  • [ISO-abbreviation] Pediatr Neonatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


69. Beck SD, Foster RS, Bihrle R, Ulbright T, Koch MO, Wahle GR, Einhorn LH, Donohue JP: Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol; 2002 Oct;168(4 Pt 1):1402-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer.
  • PURPOSE: Patients who require post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for metastatic testis cancer derive therapeutic benefit from resection of teratoma but resection of necrosis is not beneficial.
  • We determine if the absence of teratoma in the orchiectomy specimen is a reliable predictor of the absence of teratoma in the retroperitoneum at post-chemotherapy retroperitoneal lymph node dissection.
  • MATERIALS AND METHODS: A retrospective review of the Indiana University testis cancer data base was performed.
  • A total of 644 patients who underwent retroperitoneal lymph node dissection after induction chemotherapy only were selected for study.
  • The presence or absence of teratoma in the orchiectomy specimen and volume of retroperitoneal tumor were analyzed as predictors of retroperitoneal teratoma at post-chemotherapy retroperitoneal lymph node dissection.
  • RESULTS: Of the patients with teratoma in the orchiectomy specimen 85.6% had an element of teratoma in the retroperitoneum, and of those without teratomatous elements in the orchiectomy specimen 48% had teratoma in the retroperitoneum (p <0.00001).
  • Increasing volumes of retroperitoneal tumor were associated with a higher probability of discovering teratoma at post-chemotherapy retroperitoneal lymph node dissection.
  • CONCLUSIONS: The absence of teratoma in the orchiectomy specimen does not reliably predict the absence of teratoma in the surgical specimen at post-chemotherapy retroperitoneal lymph node dissection.
  • Post-chemotherapy surgery is indicated if retroperitoneal tumor remains after chemotherapy irrespective of the presence or absence of teratoma in the orchiectomy specimen.
  • [MeSH-major] Lymph Node Excision. Orchiectomy. Retroperitoneal Neoplasms / secondary. Teratoma / secondary. Testicular Neoplasms / surgery. Testis / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Neoplasm Staging. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2002 Oct;168(4 Pt 1):1405 [12352403.001]
  • (PMID = 12352402.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Vimla N, Kumar L, Thulkar S, Bal S, Dawar R: Primary malignant melanoma in ovarian cystic teratoma. Gynecol Oncol; 2001 Aug;82(2):380-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant melanoma in ovarian cystic teratoma.
  • BACKGROUND: Malignant degeneration of benign cystic teratoma of the ovary is rare.
  • Occurrence of melanoma in an ovarian cystic primary teratoma in the absence of a demonstrable extraovarian primary is even rarer.
  • Histopathological examination of the specimen revealed malignant cystic teratoma with the presence of a melanoma component.
  • Postoperatively, she received combination chemotherapy using cisplatin and dacarbazine.
  • She is on regular follow-up and continues to be disease-free, 18 months after treatment.
  • CONCLUSION: Primary malignant melanoma in cystic teratoma of the ovary is extremely rare.
  • Clinical presentation is similar to that of primary epithelial ovarian cancer.
  • Surgery remains the mainstay of treatment.
  • [MeSH-major] Melanoma / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Academic Press.
  • (PMID = 11531299.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


71. Rim SY, Kim SM, Choi HS: Malignant transformation of ovarian mature cystic teratoma. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):140-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of ovarian mature cystic teratoma.
  • There have been few studies concerning the clinical pathology of malignant transformation arising in ovarian mature cystic teratoma (MCT).
  • Demographic characteristics, symptoms, signs, stage, mode of therapy, and results of follow-up were reviewed retrospectively.
  • All the patients had surgery, and seven of them had adjuvant chemotherapy and two had adjuvant chemoradiation.
  • All the patients in stage I survived until the period of follow-up, and their average survival time was 31.8 months.
  • Accordingly, it is considered helpful for preventing and early detection of the malignant transformation to have regular ovary examination through pelvic ultrasonogram during the reproductive age.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Teratoma / pathology. Teratoma / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Chemotherapy, Adjuvant. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovariectomy / methods. Retrospective Studies. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445624.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Benoit MF, Hannigan EV, Strickland JL: Recurrent mature cystic ovarian teratoma in adolescence: atypical case of the growing teratoma syndrome. Obstet Gynecol; 2005 May;105(5 Pt 2):1264-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent mature cystic ovarian teratoma in adolescence: atypical case of the growing teratoma syndrome.
  • BACKGROUND: A primary mature cystic ovarian teratoma was diagnosed in an adolescent female.
  • She was followed up after initial exploration with computed tomography, pelvic ultrasonography, and serum tumor markers.
  • CASE: This is a report of the growing teratoma syndrome in a young woman with a primary diagnosis of a mature cystic ovarian teratoma not treated with adjuvant chemotherapy.
  • CONCLUSION: The growing teratoma syndrome is an uncommon condition.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Ovarian Cysts / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Biopsy, Needle. Disease Progression. Female. Follow-Up Studies. Humans. Immunohistochemistry. Laparotomy / methods. Neoplasm Staging. Ovariectomy / methods. Syndrome. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography, Doppler

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863604.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Tzortzatos G, Sioutas A, Schedvins K: Successful pregnancy after treatment for ovarian malignant teratoma with growing teratoma syndrome. Fertil Steril; 2009 Mar;91(3):936.e1-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful pregnancy after treatment for ovarian malignant teratoma with growing teratoma syndrome.
  • OBJECTIVE: To report a case of successful IVF-pregnancy after treatment for ovarian growing teratoma syndrome.
  • PATIENT(S): A 20-year-old woman, gravida 0 para 0, was diagnosed with malignant teratoma of the ovary.
  • She was treated by unilateral salpingo-oophorectomy and chemotherapy.
  • A couple of years later she was diagnosed with growing teratoma syndrome.
  • INTERVENTION(S): Fertility-preserving surgery with unilateral salpingo-oophorectomy and chemotherapy.
  • RESULT(S): After treatment for ovarian immature teratoma and growing teratoma syndrome the patient was free of the disease.
  • She underwent in vitro fertilization treatment with autologous embryo transfer and gave birth to a healthy child.
  • CONCLUSION(S): Growing teratoma syndrome is an extremely rare metastatic complication of a malignant germ cell tumor after a combination treatment with surgery and adjuvant chemotherapy.
  • This case shows that successful pregnancy outcome is possible after effective treatment for ovarian growing teratoma syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fallopian Tubes / surgery. Infertility, Female / therapy. Ovarian Neoplasms / therapy. Ovariectomy / adverse effects. Teratoma / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Embryo Transfer. Female. Fertilization in Vitro. Humans. Live Birth. Neoplasm Metastasis. Pregnancy. Syndrome. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Female Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152879.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Tanaka T, Toujima S, Utsunomiya T, Yukawa K, Umesaki N: Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Oncol Rep; 2008 Jul;20(1):13-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery.
  • Minimal optimal surgery without chemotherapy is often performed for patients with ovarian immature teratoma, which frequently occurs in young women who hope for future pregnancies.
  • If tumors recur after the operation, anticancer drug chemotherapy is often administered, although few studies have highlighted differences between the recurrent and the primary tumor cells.
  • Therefore, we have established experimental animal models of recurrent ovarian immature teratoma cells after optimal surgery and characterized the anticancer drug sensitivity and antigenicity of the recurrent tumors.
  • Surgically-excised tumor cells of a grade II ovarian immature teratoma were cultured in vitro and transplanted into nude mice to establish stable cell lines.
  • Differential drug sensitivity and antigenicity of the tumor cells were compared between the primary and the nude mouse tumors.
  • Cultured primary cells showed a remarkably high sensitivity to paclitaxel, docetaxel, adriamycin and pirarubicin, compared to peritoneal cancer cells obtained from a patient with ovarian adenocarcinomatous peritonitis.
  • The drug sensitivity of teratoma cells to 5-fluorouracil, bleomycin or peplomycin was also significantly higher.
  • However, there was no significant difference in sensitivity to platinum drugs between the primary teratoma and the peritoneal adenocarcinoma cells.
  • As for nude mouse tumor cells, sensitivity to 12 anticancer drugs was significantly lower than that of the primary tumor cells, while there was little difference in sensitivity to carboplatin or peplomycin between the primary and nude mouse tumor cells.
  • In conclusion, ovarian immature teratomas with normal karyotypes have a malignant potential to recur after minimal surgery.
  • During nude mouse transplantation, SMA-overexpressing cells appeared to be selectively excluded and nude mouse tumor cells were less sensitive to the majority of anticancer drugs than the primary tumor cells.
  • These results indicate that after optimal surgery for ovarian immature teratoma, recurrent cells can be more resistant to anticancer drugs than the primary tumors.
  • Therefore, it is likely that adjuvant chemotherapy lowers the risk of ovarian immature teratomas recurring after optimal surgery.
  • BEP and PBV regimens are frequently given to teratoma patients.
  • However, paclitaxel/carboplatin or docetaxel/carboplatin, which are the most effective chemotherapy treatments for epithelial ovarian cancer patients, are considered to be an alternative regimen, especially in the prevention of reproductive toxicity.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Humans. Karyotyping. Mice

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575713.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


75. Saito J, Takayama H, Kakuta Y, Miyagawa Y, Tsujihata M, Nishimura K, Nonomura N, Okuyama A: [The growing teratoma syndrome report of a case]. Nihon Hinyokika Gakkai Zasshi; 2006 Sep;97(6):796-800
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The growing teratoma syndrome report of a case].
  • Histopathological examination of the specimen revealed yolk sac tumor and mature teratoma.
  • A single course of BEP (bleomysin, etoposide and cisplatin), two courses of chemotherapy consisting of nedaplatin and irinotecan, and three courses of TIP (paclitaxel, ifosfamide and cisplatin) were delivered.
  • Histologic examination of the resected specimens revealed mature teratoma without malignant components.
  • These results were compatible with growing teratoma syndrome.
  • The resected specimens revealed mature teratoma without malignant components.
  • [MeSH-major] Endodermal Sinus Tumor. Neoplasms, Multiple Primary. Teratoma. Testicular Neoplasms
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Orchiectomy. Remission Induction

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17025213.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


76. Li Y, Jiang Y, Song S: [Diagnosis and treatment of primary retroperitoneal teratoma]. Zhonghua Wai Ke Za Zhi; 2000 Dec;38(12):892-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of primary retroperitoneal teratoma].
  • OBJECTIVE: To study the diagnosis and treatment of primary retroperitoneal teratoma in adults.
  • METHODS: The clinical data of 36 adult patients with primary retroperitoneal teratoma were reviewed.
  • CONCLUSIONS: Malignant metastasis of retroperitoneal teratoma is closely related to the age of adults.
  • Early radical resection is the optimal treatment.
  • Adjuvant chemotherapy can induce a short-time remission in those with germ cell elements.
  • [MeSH-major] Retroperitoneal Neoplasms. Testicular Neoplasms

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11832188.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


77. Wei F, Jiang Z, Yan C: Analysis of 20 mature ovarian cystic teratoma cases in postmenopausal women. Chin Med J (Engl); 2001 Feb;114(2):137-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of 20 mature ovarian cystic teratoma cases in postmenopausal women.
  • OBJECTIVE: To study the incidence of malignant change, diagnosis and management of mature cystic teratomas in postmenopausal women.
  • METHODS: Twenty cases of mature cystic teratoma in postmenopausal women admitted to our hospital between January 1977 and January 1997 was retrospectively reviewed and evaluated.
  • RESULTS: The number of postmenopausal patients with mature cystic teratoma (20) accounted for 7.6% of the total number of patients with benign ovarian teratomas (263).
  • CONCLUSION: In postmenopausal women, mature ovarian cystic teratoma should be treated as lowly malignant and should be paid much attention.
  • [MeSH-major] Ovarian Neoplasms / pathology. Postmenopause. Teratoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy. Female. Humans. Hysterectomy. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780192.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


78. Kumabe T, Kusaka Y, Jokura H, Ikeda H, Shirane R, Yoshimoto T: [Recurrence of intracranial germinoma initially treated with chemotherapy only]. No Shinkei Geka; 2002 Sep;30(9):935-42
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of intracranial germinoma initially treated with chemotherapy only].
  • Eight consecutive patients with intracranial germinoma underwent combination chemotherapy with BEP (bleomycin, etoposide, and cisplatin) or PE (cisplatin and etoposide) without irradiation between 1996 and 1997.
  • These 7 patients obtained complete response (CR) after treatment with chemotherapy only.
  • Although all patients obtained CR, 5 patients relapsed at a mean period of 19 months after the initial therapy.
  • Additional chemotherapy and total ventricle irradiation (24 Gy) achieved CR, but delayed seeding in the optic nerves outside the irradiated field was detected.
  • Another patient obtained CR after PE therapy, but there was not histological verification.
  • However, 35 months after the initial therapy, surgical extirpation of the recurrent tumor revealed immature teratoma.
  • One patient refused treatment for recurrence at the initial tumor site and died 42 months after the initial treatment.
  • Adequate initial therapy is absolutely essential for the treatment of intracranial germinoma.
  • The chemotherapy regimens in use today cannot be recommended as initial therapy without irradiation because of the high recurrence rates.
  • [MeSH-major] Brain Neoplasms / drug therapy. Germinoma / drug therapy. Neoplasm Recurrence, Local
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Child. Cisplatin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Follow-Up Studies. Humans. Male. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12233091.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


79. Carver BS, Shayegan B, Serio A, Motzer RJ, Bosl GJ, Sheinfeld J: Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. J Clin Oncol; 2007 Mar 20;25(9):1033-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
  • PURPOSE: The histologic finding of teratoma occurs in approximately 40% of all postchemotherapy retroperitoneal lymph node dissections (PC-RPLND).
  • We evaluated patients at our institution undergoing initial PC-RPLND for teratoma to determine their clinical outcome.
  • PATIENTS AND METHODS: We identified 210 patients from 1989 to 2003 with nonseminomatous germ cell tumors (NSGCT) who underwent initial PC-RPLND and were found to have only teratoma in the retroperitoneum.
  • RESULTS: Of the 210 patients in our series, 192 (92%) received only induction chemotherapy, and 18 (9%) required additional chemotherapy regimens.
  • PC-RPLND pathology revealed mature teratoma in 178 patients (85%), immature teratoma in 15 patients (7%), and teratoma with malignant transformation in 17 patients (8%).
  • With a median follow-up time for survivors of 37 months, disease recurred in 30 patients.
  • Of the 30 patients with disease recurrence, 10 (33%) had recurrence with teratoma, five (17%) had recurrence with teratoma with malignant transformation, and 15 (50%) had recurrence with viable germ cell tumor.
  • On multivariable analysis, residual mass size and International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification were predictors of disease recurrence (P < .0005 and = .001, respectively).
  • Patients found to have teratoma at PC-RPLND have a 10-year probability of freedom from recurrence of 80%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lymph Node Excision. Retroperitoneal Neoplasms / secondary. Teratoma / secondary. Teratoma / surgery. Testicular Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lymph Nodes / pathology. Lymph Nodes / surgery. Male. Neoplasm Staging. Neoplasm, Residual. New York City / epidemiology. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Registries. Retroperitoneal Space. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 20;25(9):1024-5 [17261852.001]
  • (PMID = 17261854.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


80. Palese MA, Su LM, Kavoussi LR: Laparoscopic retroperitoneal lymph node dissection after chemotherapy. Urology; 2002 Jul;60(1):130-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic retroperitoneal lymph node dissection after chemotherapy.
  • OBJECTIVES: To assess the operative feasibility, clinical outcomes, and complications of laparoscopic retroperitoneal lymphadenectomy (RPLND) after chemotherapy.
  • METHODS: A retrospective review of clinical records from 7 patients who underwent laparoscopic RPLND after chemotherapy was performed.
  • One patient was diagnosed with pure seminoma and one with epididymal small cell cancer.
  • All 7 patients received multiagent chemotherapy for clinical Stage IIA or higher disease, followed by laparoscopic RPLND for findings of a residual retroperitoneal mass on computed tomography or a prechemotherapy mass size greater than 3.0 cm.
  • The mean tumor diameter was 3.07 cm before chemotherapy and 1.91 cm after chemotherapy.
  • Of the 5 patients who presented with nonseminomatous germ cell tumor after orchiectomy, 3 were found to have retroperitoneal lymph nodes consistent with mature teratoma, 1 had necrotic tissue, and 1 had residual viable tumor.
  • CONCLUSIONS: Laparoscopic RPLND is a feasible operation in patients after systemic chemotherapy.
  • This technique remains challenging at this time and should be reserved for patients with limited residual disease and should only be performed at institutions with considerable laparoscopic expertise.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Node Excision / methods. Retroperitoneal Neoplasms / secondary. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Adult. Biomarkers, Tumor. Feasibility Studies. Humans. Laparoscopy / adverse effects. Laparoscopy / methods. Lymphatic Metastasis. Male. Middle Aged. Retrospective Studies. Seminoma / diagnosis. Seminoma / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12100938.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


81. Kane SV, Karpate AA, Bal M, Juvekar SL, Pai PS: Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation. Head Neck Pathol; 2009 Mar;3(1):31-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced neuronal maturation in sinonasal teratocarcinosarcoma--a unique observation.
  • Sinonasal teratocarcinosarcoma (SNTCS) is a rare and highly malignant tumour with combined features of a teratoma and carcinosarcoma.
  • We report the first case of a SNTCS in 23 year old male treated with neo-adjuvant chemotherapy followed by cranio-facial resection.
  • Tumor was excised after 4 cycles of neo-adjuvant chemotherapy.
  • The undifferentiated neuroectodermal cells were completely absent in the post chemotherapy specimen.
  • This case throws light on the morphologic evidence of chemotherapy induced maturation in the neuroectodermal component within SNTCS, an event hitherto not reported in the literature in case of SNTCS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / pathology. Cell Differentiation / drug effects. Neurons / pathology. Nose Neoplasms / pathology. Teratocarcinoma / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Immunohistochemistry. Male. Neoadjuvant Therapy. Neoplasm Staging. Otorhinolaryngologic Surgical Procedures. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 1988;45(3):148-52 [3368191.001]
  • [Cites] Otolaryngol Head Neck Surg. 1995 Mar;112(3):496-500 [7870460.001]
  • [Cites] Hum Pathol. 1998 Jul;29(7):718-22 [9670829.001]
  • [Cites] Ann Diagn Pathol. 2006 Dec;10(6):339-42 [17126251.001]
  • [Cites] Ann Diagn Pathol. 2008 Dec;12(6):415-25 [18995206.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Feb 1;62(2):159-64 [11788149.001]
  • [Cites] Pathology. 1983 Oct;15(4):413-9 [6674870.001]
  • [Cites] Pediatr Blood Cancer. 2004 Nov;43(6):687-91 [15390296.001]
  • [Cites] Cancer. 1968 Apr;21(4):714-21 [5651269.001]
  • [Cites] Cancer. 1976 Aug;38(2):818-23 [974998.001]
  • [Cites] J Surg Oncol. 1977;9(1):21-8 [839794.001]
  • [Cites] Cancer. 1984 May 15;53(10):2140-54 [6322958.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):942-7 [11844067.001]
  • (PMID = 20596986.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2807528
  • [Keywords] NOTNLM ; Neo-adjuvant chemotherapy / Neuronal maturation / Sinonasal tumours / Teratocarcinosarcoma
  •  go-up   go-down


82. Ishimaru A, Hasegawa J, Shinbo K, Arahara T, Kinoshita Y, Shimoyama E, Korehisa M, Oonuki M, Miyazawa T, Itabashi M: [A case of retroperitoneal tumor successfully resected thanks to effective chemotherapy]. Gan To Kagaku Ryoho; 2009 Jun;36(6):1007-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal tumor successfully resected thanks to effective chemotherapy].
  • We reported a case of retroperitoneal immature teratoma with embryonal carcinoma.
  • The final pathological diagnosis by operation was immature teratoma with embryonal carcinoma.
  • The effective chemotherapy reduced this tumor enough to allow successful resection.
  • Although the prognosis of immature retroperitoneal teratoma is poor, this case has survived 10 years after operation without metastasis and recurrence.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Carcinoma, Embryonal / drug therapy. Carcinoma, Embryonal / pathology. Carcinoma, Embryonal / surgery. Humans. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542726.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


83. Bi WL, Bannykh SI, Baehring J: The growing teratoma syndrome after subtotal resection of an intracranial nongerminomatous germ cell tumor in an adult: case report. Neurosurgery; 2005;56(1):188
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The growing teratoma syndrome after subtotal resection of an intracranial nongerminomatous germ cell tumor in an adult: case report.
  • The growing teratoma syndrome, as originally described with pediatric germ cell neoplasms, represents tumor recurrence, often cystic, that sometimes is observed after partial response to multimodality therapy and despite decreasing tumor serum markers.
  • The enlarging tumor consists of elements of a mature teratoma that presumably are refractory to chemotherapy or radiation.
  • To our knowledge, this is only the third case of the growing teratoma syndrome in an adult patient with nongerminomatous germ cell tumor.
  • CLINICAL PRESENTATION: A 26-year-old man had signs of recurrent obstructive hydrocephalus 6 months after multimodality treatment of a diencephalic yolk sac tumor and endoscopic third ventriculostomy.
  • Histopathological analysis demonstrated a mature teratoma.
  • CONCLUSION: Surgical resection, if feasible, is the treatment of choice for the growing teratoma syndrome to establish the correct diagnosis and prevent complications.
  • [MeSH-major] Brain Neoplasms / surgery. Neoplasms, Germ Cell and Embryonal / surgery. Neoplasms, Second Primary / diagnosis. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617603.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Geldart TR, Simmonds PD, Mead GM: Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int; 2002 Sep;90(4):451-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer.
  • OBJECTIVE: To evaluate the contribution of routine orchidectomy in the management of patients who present with advanced, metastatic, testicular germ cell cancer and who are treated with initial chemotherapy.
  • PATIENTS AND METHODS: Sixty consecutive patients presenting with metastatic testicular germ cell cancer and treated with initial chemotherapy followed by orchidectomy were identified.
  • The pathological findings at orchidectomy were compared with the pathological findings from metastatic masses resected after chemotherapy, and are reviewed with the clinical outcome.
  • RESULTS: Of the 60 orchidectomy specimens after chemotherapy, 24 (40%) contained significant histological abnormalities comprising residual invasive germ cell cancer, intratubular germ cell neoplasia and/or mature teratoma.
  • Six (10%) orchidectomy specimens contained residual invasive germ cell cancer, three nonseminomatous germ cell cancer (NSGCT) and three seminoma.
  • The patients with residual invasive NSGCT present within the testis had evidence of residual invasive NSGCT within extragonadal masses resected after chemotherapy; all three have relapsed and died from chemorefractory progressive disease.
  • CONCLUSION: Orchidectomy after chemotherapy is recommended in all patients undergoing primary chemotherapy, as a significant proportion (40%) are left with histological abnormalities that predispose to subsequent relapse.
  • Persistence of invasive NSGCT at the site of the primary tumour after chemotherapy is associated with persistence of invasive disease at other metastatic sites and is a poor prognostic finding.
  • [MeSH-major] Germinoma / surgery. Orchiectomy / methods. Testicular Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Humans. Male. Middle Aged. Prognosis. Seminoma / drug therapy. Seminoma / secondary. Seminoma / surgery


85. Fléchon A, Rivoire M, Berger N: [Surgery of residual masses after chemotherapy in patients with testicular cancer]. Rev Prat; 2007 Feb 28;57(4):389-98
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgery of residual masses after chemotherapy in patients with testicular cancer].
  • [Transliterated title] Chirurgie des masses résiduelles après chimiothérapie du cancer du testicule.
  • Cisplatin-based chemotherapy has dramatically improved the prognosis of germ cell tumours, but surgery, when applicable, remains a central part of treatment.
  • Forty five per cent and 10% of residual masses contain teratoma or active disease respectively.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Neoplasm, Residual / surgery. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Germ Cell and Embryonal / surgery. Testicular Neoplasms / drug therapy. Testicular Neoplasms / surgery
  • [MeSH-minor] Adult. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Brain Neoplasms / secondary. Brain Neoplasms / surgery. Combined Modality Therapy. Controlled Clinical Trials as Topic. Follow-Up Studies. Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Lymphatic Metastasis. Male. Positron-Emission Tomography. Postoperative Complications. Prognosis. Prospective Studies. Radiotherapy Dosage. Retroperitoneal Space. Seminoma / drug therapy. Seminoma / radionuclide imaging. Seminoma / surgery. Teratoma / surgery. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Testicular cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17455741.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 52
  •  go-up   go-down


86. Biskup W, Calaminus G, Schneider DT, Leuschner I, Göbel U: Teratoma with malignant transformation: experiences of the cooperative GPOH protocols MAKEI 83/86/89/96. Klin Padiatr; 2006 Nov-Dec;218(6):303-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoma with malignant transformation: experiences of the cooperative GPOH protocols MAKEI 83/86/89/96.
  • BACKGROUND: The designation of a teratoma with malignant transformation (TMT) refers to the occurrence of somatic non-germ cell malignancies within a teratoma.
  • PATIENTS AND METHODS: Between 1982 and 2003, 641 patients with extracranial nontesticular pure teratoma (256 coccygeal, 246 ovarian, 139 other sites) were reported to the MAKEI protocols 83/86/89/96 by various, mainly German centres.
  • Patients with teratoma and somatic malignancy were identified by database queries.
  • Two patients had coccygeal teratomas and seven ovarian tumors.
  • Resection was performed in seven patients (including both coccygeal tumors) and adjuvant chemotherapy was administered in one of them.
  • Two patients relapsed after resection, but both were cured with chemotherapy.
  • Two patients suffered from advanced tumors and both were treated with primary chemotherapy.
  • The other patient died as a result of progression of her malignant medulloepithelioma.
  • CONCLUSIONS: Malignant transformation of pure teratomas constitutes a very rare entity in children and adolescents that is most commonly observed in postpubertal girls with ovarian teratoma.
  • Compared to adult patients, similar malignant entities can be observed in association with teratoma.
  • In localised tumors, complete resection appears to be adequate, whereas chemotherapy should be considered in patients with R1- or R2-resection.
  • Cisplatinum-based chemotherapy was effective as two of four relapsed patients survived tumor free.
  • However, the ideal regimen has not yet been established and the known sensitivity of the histologic components to cytostatic drugs has to be considered in the choice of treatment.
  • [MeSH-major] Ovarian Neoplasms. Teratoma
  • [MeSH-minor] Adolescent. Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Child. Child, Preschool. Cytogenetic Analysis. Female. Humans. Infant. Infant, Newborn. Middle Aged. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / pathology. Ovary / pathology. Sacrococcygeal Region / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080331.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


87. Fan Q, Huang H, Lian L, Lang J: Characteristics, diagnosis and treatment of hepatic metastasis of pure immature ovarian teratoma. Chin Med J (Engl); 2001 May;114(5):506-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics, diagnosis and treatment of hepatic metastasis of pure immature ovarian teratoma.
  • OBJECTIVE: To analyze the characteristics of hepatic metastasis of pure immature ovarian teratoma and explore its proper diagnosis and treatment.
  • METHODS: Eighteen cases of hepatic metastasis of pure immature ovarian teratoma were included in this study.
  • The clinical stage, operation, chemotherapy and histopathology of primary and secondary tumors as well as the data from long term follow-ups were analyzed retrospectively.
  • The hepatic metastatic rate was 16.7% (3/18) in the standard adjuvant chemotherapy group but increased markedly to 31.2% (15/48) in the irregular chemotherapy group.
  • The surgical resection rate of hepatic metastasis of pure immature ovarian teratoma was 94.4% (17/18).
  • The follow-up time ranged from 3 to 205 months with a mean of 20.9 months.
  • CONCLUSIONS: The hepatic metastatic rate of pure immature ovarian teratoma could be decreased using standard adjuvant chemotherapy.
  • Suitable surgical treatment could reduce complications and improve the prognosis for patients.
  • [MeSH-major] Liver Neoplasms / secondary. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11780414.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Kim SM, Choi HS, Byun JS, Kim YH, Kim KS, Rim SY, Kim HR, Nam JH, Choi YD: Mucinous adenocarcinoma and strumal carcinoid tumor arising in one mature cystic teratoma of the ovary with synchronous cervical cancer. J Obstet Gynaecol Res; 2003 Feb;29(1):28-32
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma and strumal carcinoid tumor arising in one mature cystic teratoma of the ovary with synchronous cervical cancer.
  • Malignant transformation of mature cystic teratoma is an uncommon complication.
  • While any of the constituent tissues of a teratoma has the potential to undergo malignant transformation, squamous cell carcinoma is the most commonly associated cancer.
  • We present an unusual case of a postmenopausal woman with synchronous mucinous adenocarcinoma and strumal carcinoid tumor from one of two ovarian mature cystic teratomas (one in each ovary) with synchronous cervical cancer.
  • We suggest that malignant transformation of mature cystic teratoma and synchronous cervical cancer be treated by hysterectomy, chemotherapy, and radiotherapy.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged. Teratoma / complications. Teratoma / diagnosis. Teratoma / pathology


89. Muscatello L, Giudice M, Feltri M: Malignant cervical teratoma: report of a case in a newborn. Eur Arch Otorhinolaryngol; 2005 Nov;262(11):899-904
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant cervical teratoma: report of a case in a newborn.
  • Malignant cervical teratoma (MCT) usually appears in newborns as an enlarging mass of the neck that causes respiratory distress, requiring prompt airway control.
  • Diagnosis was benign extragonadic immature teratoma, but it was changed in MCT when cervical metastases appeared and the alpha-fetoprotein (AFP) level increased.
  • Subsequent surgical procedures and chemotherapy were necessary.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):446-50; discussion 446-50 [12632365.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):781-6 [12610174.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Feb;42(1):41-5 [14706299.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1995 Jun;104(6):496-500 [7771726.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1984 Jan-Feb;93(1 Pt 1):98-9 [6703601.001]
  • [Cites] J Pediatr Surg. 2003 Apr;38(4):E12 [12677599.001]
  • [Cites] Indian Pediatr. 1993 May;30(5):689-94 [8282403.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1993 Jul;102(7):567-9 [8333680.001]
  • [Cites] J Pediatr Surg. 1995 Feb;30(2):312-6 [7537809.001]
  • [Cites] Otolaryngol Clin North Am. 1989 Jun;22(3):621-9 [2657586.001]
  • [Cites] Laryngoscope. 1985 Oct;95(10):1262-3 [4046714.001]
  • [Cites] J Pediatr Surg. 1983 Aug;18(4):382-6 [6620078.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2002 Sep 24;65(3):241-7 [12242140.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):21-3 [2723988.001]
  • [Cites] J Otolaryngol. 1997 Aug;26(4):246-52 [9263894.001]
  • [Cites] Prenat Diagn. 1990 May;10(5):327-32 [1697071.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Jan;124(1):53-5 [11228453.001]
  • [Cites] J Clin Ultrasound. 1988 Jun;16(5):329-36 [3152390.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1987 Jan-Feb;96(1 Pt 1):61-4 [3545020.001]
  • [Cites] Pediatr Surg Int. 2000;16(5-6):333-7 [10955557.001]
  • [Cites] J Pediatr Surg. 2003 Dec;38(12):1846 [14666486.001]
  • [Cites] J Clin Ultrasound. 1984 Oct;12(8):509-11 [6436332.001]
  • [Cites] Ann Surg. 1983 Sep;198(3):398-410 [6684416.001]
  • [Cites] Pediatr Radiol. 1998 Sep;28(9):709-10 [9732501.001]
  • [Cites] Prenat Diagn. 1993 Dec;13(12 ):1079-84 [8177827.001]
  • [Cites] Plast Reconstr Surg. 1986 Mar;77(3):469-73 [3513222.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Apr;120(4):444-8 [8166978.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 1992 Nov;24(3):261-8 [1399315.001]
  • [Cites] Eur J Pediatr. 1994 Apr;153(4):276-8 [8194563.001]
  • [Cites] Prenat Diagn. 1998 Jan;18(1):51-9 [9483640.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Feb;102(2):186-90 [2113247.001]
  • [Cites] Surg Today. 1995;25(8):737-40 [8520169.001]
  • [Cites] Otolaryngol Head Neck Surg. 1987 Apr;96(4):366-8 [3108824.001]
  • [Cites] J Pediatr Surg. 2001 Aug;36(8):1244-7 [11479867.001]
  • [Cites] Surgery. 1976 Sep;80(3):297-305 [960000.001]
  • [Cites] Niger Postgrad Med J. 2002 Jun;9(2):102-4 [12163871.001]
  • [Cites] Prog Pediatr Surg. 1981;14:225-39 [7221009.001]
  • [Cites] Laryngoscope. 1998 Sep;108(9):1398-401 [9738766.001]
  • [Cites] Pediatr Surg Int. 1998 Nov;14(1-2):79-81 [9880703.001]
  • [Cites] Pediatr Pathol. 1993 Jan-Feb;13(1):21-7 [8474949.001]
  • [Cites] Hum Pathol. 1990 Mar;21(3):309-18 [1690172.001]
  • [Cites] J Pediatr Surg. 1974 Jun;9(3):389-98 [4843993.001]
  • (PMID = 15895292.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Tanaka K, Kanai M, Yosizawa J, Yamazaki Y: A case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma. J Pediatr Surg; 2005 Mar;40(3):578-80
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • The authors report a case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • Imaging studies strongly suggested Altman type III sacrococcygeal teratoma.
  • The tumor disappeared completely after chemotherapy.
  • To the authors' knowledge, this is the first case of neonatal neuroblastoma mimicking Altman type III sacrococcygeal teratoma.
  • [MeSH-major] Neuroblastoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Teratoma / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Calcinosis / diagnosis. Colostomy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Infant, Newborn. Magnetic Resonance Imaging. Male. Phosphopyruvate Hydratase / analysis. Rectum / pathology. Rectum / surgery. Remission Induction. Sacrococcygeal Region. Subcutaneous Tissue. Synaptophysin / analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793740.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Synaptophysin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


91. Fan Q, Huang H, Lian L: [The characteristics diagnosis and treatment of hepatic metastasis of simple immature ovarian teratoma]. Zhonghua Fu Chan Ke Za Zhi; 2000 Oct;35(10):613-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The characteristics diagnosis and treatment of hepatic metastasis of simple immature ovarian teratoma].
  • OBJECTIVE: To analyze the characteristics of hepatic metastasis of pure immature ovarian teratoma and explore proper diagnosis and treatment.
  • METHODS: A total of 18 cases with hepatic metastasis of pure immature ovarian teratoma were involved in this study.
  • The clinical stage, operation, chemotherapy and histopathology of primary and secondary tumor as well as the data of long term follow-up were analyzed retrospectively.
  • The hepatic metastatic rate was 16.7% (3/18) in standard adjuvant chemotherapy group but increased obviously to 31.2% (15/48) in irregular chemotherapy group.
  • The surgical resection rate of hepatic metastasis of pure immature ovarian teratoma was 94.4% (17/18).
  • The follow-up time ranged from 3-205 months with the mean of 20.9 months.
  • CONCLUSIONS: The hepatic metastatic rate of pure immature ovarian teratoma could be decreased by using standard adjuvant chemotherapy.
  • Suitable surgical treatment could reduce complication and improve the prognosis of this kind of patients.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Teratoma / diagnosis

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11372414.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Pérez-Mies B, Regojo Zapata RM, García-Fernández E, Serrano MN: Malignant teratoma of the thyroid in a pregnant woman. Ann Diagn Pathol; 2010 Aug;14(4):264-7
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid in a pregnant woman.
  • Most teratomas involving the thyroid gland are benign and occur in children.
  • Many of the cases previously described in the medical literature have fatal outcome because of spread of the tumor refractory to treatment.
  • We report a case of primary malignant teratoma of the thyroid in a 38-year-old pregnant black woman.
  • She was treated with a combination of surgery, and postoperative chemotherapy with good initial response.
  • [MeSH-major] Pregnancy Complications, Neoplastic / pathology. Teratoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin. Cisplatin. Combined Modality Therapy. Etoposide. Female. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Pregnancy

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20637432.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


93. Lee YH, Park EK, Park YS, Shim KW, Choi JU, Kim DS: Treatment and outcomes of primary intracranial teratoma. Childs Nerv Syst; 2009 Dec;25(12):1581-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and outcomes of primary intracranial teratoma.
  • PURPOSE: Until recently, postoperative adjuvant treatment for intracranial teratomas has remained controversial because of the rarity of the tumors and the heterogeneity of histologic types.
  • To define optimal therapy modalities, we retrospectively analyzed the treatment of patients with intracranial teratomas.
  • METHODS: Between 1979 and 2007, 31 patients with intracranial teratomas were treated at our institution.
  • The median follow-up time was 72.7 months (range 11 approximately 291 months).
  • Proper chemotherapy regimens were followed, such as PE (cisplatin and VP-16), PVB (cisplatin, VP-16, and bleomycin), ICE (carboplatin, VP-16, and ifosfamide), and NGGCT (etoposide, carboplatin, bleomycin, and cyclophosphamide with mesna).
  • Fifteen patients survived for more than 5 years without recurrence, irrespective of having received adjuvant therapies.
  • CONCLUSION: Treatment of intracranial teratomas is very difficult because of the heterogeneity of the tumor cells from totipotent origins.
  • Accurate histological diagnosis of teratoma subtypes is the most important factor for adequate treatment, and proper therapeutic protocols are needed to cure teratomas.
  • [MeSH-major] Brain Neoplasms / therapy. Teratoma / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Drug Administration Schedule. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuropediatrics. 1994 Feb;25(1):26-32 [8208347.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):155-67 [2991485.001]
  • [Cites] Acta Neurochir (Wien). 1995;134(3-4):130-5 [8748771.001]
  • [Cites] Neurosurgery. 2005;56(1):188 [15617603.001]
  • [Cites] Neurosurgery. 1994 Mar;34(3):524-9; discussion 529 [7514765.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10 ):556-9 [9403206.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):222-7 [9293454.001]
  • [Cites] J Neurosurg. 1998 Nov;89(5):728-37 [9817409.001]
  • [Cites] Childs Nerv Syst. 2007 Jun;23(6):713-8 [17187270.001]
  • [Cites] Med Pediatr Oncol. 1995 Jan;24(1):53-7 [7968794.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Curr Opin Neurol. 1996 Dec;9(6):419-23 [9007398.001]
  • [Cites] J Neurosurg. 1991 Apr;74(4):545-51 [1848284.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):446-55 [9046301.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):137-9 [7505047.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):369-76 [12872359.001]
  • (PMID = 19693515.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


94. Ulker V, Gedikbasi A, Numanoglu C, Ozluk Y, Saygi S, Gulkilik A, Salihoglu Y: Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy. Arch Gynecol Obstet; 2009 Aug;280(2):287-91
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising in ovarian mature cystic teratoma in pregnancy.
  • We report a case of mucinous adenocarcinoma arising from mature cystic teratoma (MCT) of the ovary ascertained incidentally during pregnancy.
  • The patient was staged as IC and adjuvant chemotherapy was applied.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Pregnancy Complications, Neoplastic / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Pregnancy.
  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099312.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


95. Martins T, Carrilho F, Gomes L, Mesquita C, Martins MJ, Carvalheiro M: Malignant teratoma of the thyroid: case report. Thyroid; 2006 Dec;16(12):1311-3
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid: case report.
  • Teratomas in the neck are rare neoplasms.
  • In contrast, thyroid teratomas in adults are malignant and have fatal outcomes because of spread of tumor refractory to treatment.
  • We report a case of a primary thyroid malignant teratoma in a 37-year-old woman.
  • She was treated successfully with a combination of surgery, postoperative cis-platinum-based chemotherapy, and radiation therapy to the neck.
  • Although the time of follow-up is short (24 months), we attribute her successful outcome to the use of this intensive therapeutic approach.
  • [MeSH-major] Teratoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17199442.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Kondagunta GV, Bacik J, Bajorin D, Dobrzynski D, Sheinfeld J, Motzer RJ, Bosl GJ: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol; 2005 Dec 20;23(36):9290-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors.
  • RESULTS: Two hundred eighty-two of 289 patients (98%) achieved a complete response; 269 (93%) responded to chemotherapy alone and 13 (5%) responded to chemotherapy plus surgical resection of viable disease (GCT other than mature teratoma).
  • Sixty-two of 204 patients (30%) with nonseminoma had findings of teratoma or viable GCT at postchemotherapy surgery.
  • CONCLUSION: Four cycles of EP is a highly effective therapy for patients with good-risk GCT, with a high cure rate, low relapse rate, and little evidence of late relapse.
  • Postchemotherapy surgery resection of residual disease remains an important aspect of treatment for these patients.
  • Four cycles of EP is acceptable as a standard regimen for the treatment of good-risk metastatic GCT, and serves as an alternative to three cycles of bleomycin and etoposide before cisplatin.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Germ Cell and Embryonal / drug therapy. Retroperitoneal Neoplasms / drug therapy. Testicular Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jun 1;24(16):2597-8; author reply 2598-9 [16735718.001]
  • (PMID = 16361627.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5T32-CA-09207-26
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; VP-P protocol
  •  go-up   go-down


97. Shonubi AM, Musa AA, Akiode O, Salami BA, Kingu HJ, Adnan SM: Mature sacrococcygeal teratoma: a case report and literature review. West Afr J Med; 2004 Apr-Jun;23(2):176-9
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature sacrococcygeal teratoma: a case report and literature review.
  • BACKGROUND: Sacrococcygeal teratomas are derived from embryonic germ cell layers.
  • Modern imaging technique may be helpful to delineate the extent of the mass but surgical excision is generally indicated at the time of detection.
  • RESULTS: A three day old female baby presented with a mature sacrococcygeal teratoma containing well-developed limb buds.
  • CONCLUSION: Sacrococcygeal teratoma is a rare tumour that may be benign or malignant.
  • Complete excision is the primary therapy and is adequate if the tumour is benign.
  • Chemotherapy and radiotherapy are however indicated in malignant cases and in recurrence after previous excision.
  • [MeSH-major] Sacrococcygeal Region. Teratoma
  • [MeSH-minor] Biopsy. Female. Humans. Infant, Newborn. Nigeria. Postoperative Care / methods. Rare Diseases / blood. Rare Diseases / congenital. Rare Diseases / diagnosis. Rare Diseases / surgery. Skin Care / methods. Surgical Flaps. Tomography, X-Ray Computed. Treatment Outcome. Wound Healing. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15287301.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Nigeria
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 24
  •  go-up   go-down


98. Dolendo MC, Lin TP, Tat OH, Chong QT, Timothy LK: Parkinsonism as an unusual presenting symptom of pineal gland teratoma. Pediatr Neurol; 2003 Apr;28(4):310-2
Genetic Alliance. consumer health - Teratoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parkinsonism as an unusual presenting symptom of pineal gland teratoma.
  • We report a case of a 14-year-old Chinese boy with immature teratoma of the pineal gland who manifested with parkinsonism.
  • Diagnostic evaluation revealed hydrocephalus and an immature teratoma of the pineal gland extending to the thalamus.
  • An urgent ventriculoperitoneal shunt was inserted, and chemotherapy was given to reduce the tumor size.
  • Features consistent with the growing teratoma syndrome were noted during this period.
  • Secondary parkinsonism is a rare presentation of pineal gland tumors and has not been reported in association with the growing teratoma syndrome.
  • [MeSH-minor] Adolescent. Combined Modality Therapy. Disease Progression. Equipment Failure. Follow-Up Studies. Humans. Hydrocephalus / diagnosis. Hydrocephalus / etiology. Image Enhancement. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy. Ventriculoperitoneal Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12849888.001).
  • [ISSN] 0887-8994
  • [Journal-full-title] Pediatric neurology
  • [ISO-abbreviation] Pediatr. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Nonomura N, Oka D, Nishimura K, Nakayama M, Inoue H, Mizutani Y, Miki T, Okuyama A: Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors. Int J Urol; 2007 Jun;14(6):527-31
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors.
  • BACKGROUND: The paclitaxel, ifosfamide, and cisplatin regimen has been used to treat metastatic testicular cancer with successful results.
  • We investigated the usefulness of a paclitaxel, ifosfamide, and nedaplatin (TIN) regimen as salvage therapy for patients with advanced testicular germ cell tumors (GCTs).
  • The treatment was performed as salvage therapy for cases refractory to therapies, such as bleomycin, etoposide and cisplatin, and irinotecan with nedaplatin.
  • RESULTS: Seven out of eight patients achieved a disease-free status after chemotherapy, followed by surgical resection of the residual tumor.
  • Six of the seven patients have continued to show no evidence of disease after salvage therapy, with a median follow-up period of 27 months, but one patient developed a 'growing teratoma syndrome' in the mediastinum 31 months after TIN chemotherapy.
  • All patients developed grade 4 leukocytopenia.
  • Only one patient developed grade 2 sensory neuropathy and no patient developed nephrotoxicity.
  • CONCLUSION: The TIN regimen was efficacious and well-tolerated as salvage chemotherapy for Japanese patients with advanced GCTs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasms, Germ Cell and Embryonal / drug therapy. Salvage Therapy / methods. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Acute Kidney Injury / prevention & control. Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Organoplatinum Compounds / administration & dosage. Organoplatinum Compounds / adverse effects. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17593098.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


100. Chen YH, Chang CH, Chen KC, Diau GY, Loh IW, Chu CC: Malignant transformation of a well-organized sacrococcygeal fetiform teratoma in a newborn male. J Formos Med Assoc; 2007 May;106(5):400-2
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation of a well-organized sacrococcygeal fetiform teratoma in a newborn male.
  • We report herein a case of a male newborn with a sacrococcygeal fetiform teratoma (FT).
  • The baby presented with a large coccygeal teratoma.
  • Postoperative follow-up was uneventful until the teratoma recurred 11 months later as a malignancy.
  • After undergoing a second operative procedure accompanied by chemotherapy, he has been doing well for 18 months.

  • Genetic Alliance. consumer health - Sacrococcygeal Teratoma.
  • Genetic Alliance. consumer health - Teratoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561476.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement